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Abstract 
 
Colorectal cancer accounts for 13% of all cancers in the UK. Surgical resection 
offers the best prospects of a cure but 45% of these patients will still develop 
metastases with haematogenous spread suspected to be the main method of 
dissemination to distant sites. Circulating tumour cells (CTCs) are intermediaries 
in this process and whilst their exact role remains unclear, their presence has 
proven to be an independent prognostic factor in breast, prostate and colorectal 
cancer. The capture and isolation of intact CTCs for mutational analysis could 
not only shed light on the process of metastases but could guide therapy.  
 
However, CTCs are extremely rare events in the blood stream and their 
detection and capture have been elusive, particularly the capture of sufficient 
numbers to allow mutational analysis. Capture of CTCs based on their larger 
size in comparison to most other cells in the blood, combined with 
immunohistochemical characterization to identify them as tumour cells has 
shown promise in the past. This method of capture also causes minimal 
disruption to the cell structure and therefore enables accurate mutational 
analysis.  
 
In this study a novel filtration based technology was used to capture and isolate 
CTCs from the peripheral blood of colorectal patients to allow assessment of 
their KRAS mutational status.  
 
An immunohistochemical staining protocol to identify colorectal CTCs captured 
from whole blood was developed and incorporated into the functioning of the 
filtration device. Two patient populations were examined to identify and 
enumerate colorectal CTCs: those undergoing liver surgery for colorectal liver 
metastases and those undergoing palliative therapy for inoperable disease. 
Significant numbers of CTCs were only identified in those with inoperable 
disease.  
 
Mutational analysis was performed using a commercially available cast-PCR kit 
designed to detect KRAS mutations. Preliminary experiments found that DNA 
extracted directly from captured CTCs was insufficient in quantity and quality for 
successful analysis. Whole genome amplification of DNA from intact cells was 
therefore performed prior to mutational analysis. A multi-step protocol of cell 
capture, whole genome amplification and cast PCR was developed and tested 
on patient samples to show that KRAS mutational analysis could be performed 
on CTCs using this filtration based technology. 
 
In conclusion, the study shows that capture and isolation of intact CTCs is 
possible using filtration based technology. However, even in patients with 
relatively high numbers of CTCs, whole genome amplification needs to be 
performed prior to performing mutational analysis. 
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1.0	 Introduction	
 
1.1	 Colorectal	cancer	
 
Colorectal cancer (CRC) is the third commonest cancer in men and women in the 
UK, accounting for 13% of all cancers with 40,695 new cases being diagnosed in 
2011 (Cancer Research UK Information Resource Centre, 2014). The age-
standardised incidence rate is significantly lower in England compared with Wales, 
Scotland and Northern Ireland. There has existed a north-south divide in colorectal 
cancer incidence since the 1990s with a much clearer division for men than for 
women. The highest rates are therefore found amongst men from Scotland, 
Northern Ireland and north of England (National cancer intelligence network, 2012).   
Figure 1.1 Average number of cases and age-specific incidence rates for colorectal 
cancer per 100,000 population, UK (2008). Cancer Research UK.  
 
Incidence is strongly related to age (see figure 1.1). Between 2008 and 2010, 73% 
of cases were in people aged 65 and over. With an increasing age, the incidence 
gap between men and women also increases, with the widest gap in the 65-74 year 
age group (17:10). In the over 85s, this falls back to 15:10. 
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Surgical resection still offers the best prospects of a cure but despite surgery around 
45% of patients will still develop distant metastases [1]. The overall 5-year survival 
depends on the stage of disease at the time of resection. Staging for CRC is based 
on the Tumour, Node and Metastasis (TNM) staging system with reference to the 
size of the tumour and its penetration of the bowel wall (T), spread to regional lymph 
nodes (N) and distant metastases (M). Stages I and II refer to tumours restricted to 
the bowel wall whilst stage III indicates spread to regional lymph nodes and stage IV 
indicates distant metastases. The 5-year survival accordingly decreases from 90% 
in stage I disease to 8% in stage IV [1]. 
 
In colorectal cancer metastases occur through hematogenous and lymphatic spread 
with tumour cells shed from the primary tumour disseminating to distant sites and 
eventually leading to metastases. For colorectal cancer the preferred sites of 
metastases are the liver, lungs and bone marrow [1] where colonization is enabled 
through recognition of endothelial cell antigens and response to local growth factors 
[2]. 
 
1.2	 Process	of	metastases	
 
The majority of cancer deaths from solid tumours occur due to metastases from the 
primary tumour infiltrating vital organs rather than from the primary itself. Studies 
show that metastases account for 90% of cancer deaths caused by solid tumours 
[3]. Understanding the process of metastases has therefore been of much interest to 
physicians and researchers alike.  
 
For metastatic dissemination to occur, a cancer cell from the primary tumour must 
execute a sequence of steps: locally invade the surrounding tissue, enter the 
microvasculature of the lymph and blood system (intravasation), survive and 
disseminate in the bloodstream to microvessels of distant tissues, exit from the 
bloodstream (extravasate), survive the microenvironment of distant tissues and 
finally adapt to the foreign microenvironment in such a way as to enable proliferation 
and formation of a secondary tumour (colonisation) [2, 4]. Whilst we understand 
some of the initial phases leading to dissemination, we are still many years of 
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research away from understanding the interactions that take place during 
colonisation [4]. 
 
The first clinical indication of dissemination may come from the presence of cancer 
cells in the lymph node draining the tumour but this is often a dead end rather than 
an intermediary post to distant sites [5]. In fact the majority of spread to distant sites 
occurs in the blood through hematogenous dissemination [6, 7]. For tumours arising 
from epithelial tissues (carcinomas), the cells which are normally immobile within 
epithelial sheets must break free of the tight bindings to neighboring cells and 
basement membranes by adherens junctions, tight junctions, desmosomes and 
hemi-desmosomes [8]. It is uncertain whether cells obtaining the ability to break free 
from these attachments and invade adjacent stromal compartments is part of the 
natural progression of a tumour or whether it is an accidental product of multiple 
genetic and epigenetic mutations taking place with a Darwinian like selection of cells 
with these capabilities. If cells are selected for having malignant traits, this would 
imply that such traits would be locally advantageous within the primary tumour 
environment. The alternative is that evolution of cells with greater proliferative and 
survival ability within the primary tumour develop the capability, as a consequence 
of their phenotypic state, to respond to signals that induce malignant traits. [9]  
 
An important recent development in understanding the process of metastasis is that 
cancer cells within individual tumours are very heterogeneous with populations 
organized in a hierarchy consisting of self-renewing stem cells, progenitor (partially 
differentiated) cells and fully differentiated end-stage cells [10, 11]. These cancer 
stem cells (CSCs) don’t have the same biological properties as normal tissue stem 
cells but are so named because of their enhanced tumour-initiating potential relative 
to other cancer cells. The importance of their discovery is that many of the high-
grade malignancy traits can be traced to these subpopulations of CSCs such as 
motility, invasiveness and resistance to apoptosis. Their most central trait might be 
their ability to seed new tumours, as seen when experimentally implanted into 
appropriate animal hosts [4]. Although they represent a tiny fraction of cells within 
most tumours, they may be the critical cells driving malignant progression. 
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Tumours tend to metastasize to certain organs and sites specific to that tumour. 
This was first reported by Stephen Paget in the 19th century when he published the 
‘seed and soil’ hypothesis outlining the non-random pattern of metastases [12]. He 
described how certain tumour cells (seeds) have an affinity to the environment of 
certain target organs (soil). It is now accepted that certain tumours selectively 
metastasise to specific organs. Recent studies of CSCs has also shown that when 
they interact with particular host tissues’ microenvironment their biology is modified, 
allowing them to develop into metastases [13]. 
 
1.3	 Circulating	tumour	cells	
 
Circulating tumour cells (CTCs) is the term given to disseminated tumour cells found 
in the circulation. It is estimated that approximately 1x106 tumour cells per gram of 
tissue are shed daily into the bloodstream with a few of them having metastatic 
potential [14, 15]. Although circulating cells were first described by Ashworth in 1869 
they were not actually captured and accessed until over a century later [16]. Studies 
have now confirmed the malignant nature of circulating tumour cells and their 
genetic association with the primary tumour [17, 18]. However their presence alone 
does not necessarily equate to metastasis formation as they may not have the 
necessary attributes to initiate tumour growth [19]. 
 
1.3.1	 Methods	of	detection	
 
Immunohistochemical methods allowed the initial identification of tumour cells and 
differentiation from normal cells in the circulation [20]. These methods are based on 
the use of monoclonal antibodies targeted to certain surface or epithelial antigens to 
label CTCs and then visualise these antibody-labelled cells under microscopy. The 
commonest antibodies used are those targeted against cytokeratins (CKs). 
Immunohistochemical detection allows morphological analysis as there is no need 
for lysis of cells as with PCR-based methods. The sensitivity of these methods, 
however, are low due to variable expression of antigens found within individual 
tumours and low frequency of cells identified in patients [1]. The specificity is also 
controversial as false-positive results are reported due to non-specific antibody 
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binding to normal blood cells [21, 22]. Additionally, these methods are labour 
intensive making routine, high-throughput use difficult [23]. 
 
With the development of technologies in flow cytometry came the ability to sort 
through large numbers of cells very quickly. This used the combined methods of 
digital microscopy and fluorescence-activated flow cytometry (FACS) to 
automatically screen samples based on nuclear and surface characteristics and sort 
the cells of interest using certain parameters [24]. This automated system also 
increased the sensitivity of detection and allowed the identification of 1 tumour cell 
in 106 normal cells [25]. 
 
However, it was the advent of polymerase chain reaction (PCR) that allowed 
detection of tumour cells with much higher sensitivity. PCR is a method that allows 
in vitro amplification of a DNA sequence using oligo-nucleotide primers specific to it. 
The process is carried out in a thermo-cycler where repeated cycles of heating and 
cooling results in exponential amplification of the targeted gene sequence [26]. In 
reverse-transcription PCR (RT-PCR) a sequence of RNA is used as the template 
and therefore an extra step of converting RNA to cDNA (reverse transcription) takes 
place prior to the amplification stage. Hence, PCR-based methods can be used to 
detect both RNA and DNA markers. DNA has the advantage of being more stable 
than RNA but this means it may be detected in blood after release from dying cells. 
Therefore the detection of CTC specific DNA does not necessarily indicate presence 
of viable CTCs [24]. Additionally, DNA markers are based on specific genetic 
abnormalities that occur in certain types of cancer but there is evidence that these 
abnormalities may not be universally present in all disseminated tumour cells [27]. 
The most commonly used markers in colorectal cancer include the KRAS and p53 
genes [28, 29]. Detection through use of mRNA, which encodes for antigens specific 
to both the malignant phenotype as well as the normal parental tissue, is also used 
to detect CTCs. This is based on the idea that mRNA is relatively unstable and 
therefore, if detected in the circulation of patients, likely indicates the presence of 
viable tumour cells in the blood as normal tissue cells should not be present here 
[30]. RT-PCR of tumour-specific mRNA has greater sensitivity than protein-based 
techniques, in the range of 1 tumour cell amongst 106 - 107 normal cells [31, 32] but 
is hampered by numerous false-positive results from the expression of markers by 
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non-tumour cells, false activation of promoters by ubiquitous transcription factors, 
amplification of pseudo-genes or contamination by genomic DNA during the cDNA 
reaction [33, 34]. 
 
1.3.2	 CTC	enrichment	techniques	
 
Enrichment of the CTC population from the initial sample is required for several 
methods of detection. This can be performed based on their physical properties, 
their selection utilizing the expression of epithelial antigens or by removing non-
epithelial cells.  
 
Capture techniques based on the physical properties of CTCs include density 
gradient centrifugation where the use of a medium such as Ficoll-Histopaque allows 
separation of whole blood fractions by allowing the passage of heavier particles 
(such as erythrocytes) through the medium during centrifugation whilst particles with 
a lower density are layered above it. As CTCs have a similar density to white blood 
cells [35], they are caught in the mononuclear interphase layer. This technique, 
however, has failed to show high CTC recovery due to the high number of 
contaminating mononuclear cells amongst which they are mixed [36-39]. OncoQuick 
technology is a variant which uses a porous barrier within the centrifugation tube to 
reduce loss of CTCs due to migration into other layers and allows greater depletion 
of mononuclear blood cells [40]. Whole blood samples can also have erythrocyte 
lysis performed using a suitable solution, with subsequent centrifugation leaving 
behind CTCs within the cell pellet. Whilst this doesn’t isolate CTCs specifically, it is 
easily performed in clinical practice and has a low cost. 
 
Currently, one of the most commonly used methods for CTC enrichment is 
immunomagnetic separation where ferrofluids are coated with antibodies or 
individual antibodies conjugated to magnetic molecules to allow extraction of tumour 
cells bearing the corresponding antigens. The extraction uses a powerful magnet to 
retain the targeted cells whilst the rest of the sample passes by. The antibodies can 
be used for either positive or negative selection. Positive selection involves 
antibodies specific to epithelial antigens being used to retrieve tumour cells from the 
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sample, whilst negative selection uses antibodies usually targeted to white blood 
cells to remove them from the sample.  
 
The CellSearch system (Veridex, Huntingdon Valley, PA) is such a system that uses 
a ferrofluid coated with an antibody targeting epithelial cell adhesion molecules 
(EpCAM) found on epithelial cells. Selected cells are distinguished to be CTCs if 
they are round or oval in shape, stain with one or more of the antibodies targeted to 
CK8, CK18 or CK19 which are found in colorectal cancer cells, do not stain with an 
antibody targeted to CD45 (to ensure they are not leukocytes) and stain positive 
with diamidino-2-phenylindole (DAPI) to show the presence of a nucleus (to ensure 
they are not cell fragments). Photographs of cells meeting these characteristics are 
automatically taken by the machine and presented to a technician who confirms 
their identity as CTCs. The results from CellSearch have been shown to reliably 
detect 1-2 cells per 7.5ml sample and are reproducible amongst multiple samples 
and multiple operators. Additionally, no non-cancer patients have been found to 
have >1 CTC in 7.5ml blood samples using this system which suggests that 
specificity is fairly high [41]. However, it is expensive, relatively labor intensive and 
suffers from very variable recovery rates (9%-90%) [42]. There is still conflicting 
evidence as to the results concerning the superiority of immunomagnetic enrichment 
over other techniques as it has been shown to have relatively poor sensitivity [43]. 
 
Perhaps the most successful technology to date is the CTC-chip which captures 
CTCs using antibodies conjugated to the surface of micro posts within a microflow 
chamber. It has been used to effectively isolate CTCs at high volumes from multiple 
metastatic cancers [44, 45]. Yet, whilst viable CTCs with a high purity can be 
obtained, the capture efficiency is still limited by the variability of surface antigen 
expression. The throughput time and processing time are also limited by a slow 
maximal flow rate [46]. 
	
1.3.3	 Filtration	based	enrichment	of	CTCs	
 
Isolation of CTCs arising from epithelial tissues can be performed by filtration, based 
on their larger size (20-30 µm) in relation to other components of blood [47]. This is 
a relatively inexpensive, efficient and fast method of CTC enrichment and is a 
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technique of cell capture dating back to the 1960s [48-52]. Although most CTCs are 
indeed larger than leukocytes, there is a large variation in their size [53] and filters 
with pores of 8µm in diameter have been found to be the optimal size for CTC 
capture [54] whilst allowing smaller erythrocytes and leukocytes to pass through 
[48]. Older polycarbonate filters were fabricated with track etching, had low CTC 
capture efficiency and suffered from frequent clogging of the filter but the modern 
microfabricated filters have proved better at CTC enrichment [42, 55-57].  
 
Several filtration devices have been developed to prevent clogging and aid retrieval 
of captured CTCs [58, 59] but whilst these have proven effective with spiked 
samples, the heterogenous nature of CTCs in patient samples mean their validation 
is still awaited [47]. 
 
1.4	Cytokeratins	
 
Cytokeratins (CK) are intermediate filament forming proteins that perform a variety 
of functions within epithelial cells including the provision of mechanical support and 
form part of the cytoskeleton. Two types of CKs are recognised, acidic type 1 (CK 9-
23) and basic type 2 (CK 1-8). The very diverse pattern of CK expression that 
correlates with pathways of epithelial differentiation means they can be used as 
markers in the identification of different epithelial cells and tissues. Because primary 
tumours and metastases share the same pattern of CKs, they have now become a 
crucial tool in the histological diagnosis of carcinomas and are used to identify the 
origin of metastatic cells [60-63]. CK typing is especially useful in cases such as 
poorly differentiated carcinomas invading adjacent tissues where the accurate origin 
is difficult to determine. Table 1.1 lists commonly expressed CKs in different 
carcinomas. 
 
Carcinoma Cytokeratins 
Hepatocellular carcinoma 8, 18 
Adenocarcinoma of colon type 1 8, 18, 19 
Adenocarcinoma of colon type 2 8, 17, 18, 19 
Adenocarcinoma of stomach 7, 8, 18, 19 
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Adenocarcinoma of pancreas 7, 8, 17, 18, 19 
Squamous cell carcinoma of 
oesophagous 
4, 5, 8, 14, 15, 16, 17, 19 
Squamous cell carcinoma of anus 4, 5, 6, 8, 10, 11, 14, 15, 16, 17, 18, 
19 
Ductal adenocarcinoma of breast 
(type1) 
7, 8, 18, 19 
Undifferentiated carcinoma of 
bronchus (large-cell type) 
6, 7, 8, 17, 18, 19 
Solid carcinoma of maxillary sinus 5, 8, 17, 18, 19 
 
Table 1.1 Cytokeratins expressed in carcinomas of different origins 
 
Cytokeratins 7, 8, 18 and 19 are commonly expressed in simple epithelia [62] and 
can be used in the differentiation of adenocarcinomas of the gastrointestinal system, 
with CK7 being consistently absent in colon adenocarcinoma [62, 64-67]. However, 
as shown in the table above, these CKs are also found in various other sites and 
therefore each CK by itself is non-specific.  
 
1.5	 Correlation	of	CTCs	with	outcomes		
 
In spite of the limitations of the current technologies in detecting CTCs, several large 
studies have been performed to evaluate the use of CTC detection and 
enumeration. The majority have used immunomagnetic separation in the form of 
CellSearch as it has been validated and standardized. These have shown that the 
presence of CTCs in peripheral blood is an independent prognostic factor in patients 
with breast [68-70], prostate [71-73] and colorectal [74] cancer. However, despite 
the processing of as much as 50ml of blood in some studies, CTCs were only 
detected in half of the patients, highlighting the need for more sensitive studies [70]. 
Other studies have correlated prognostic outcomes with RT-PCR performed on the 
mononuclear cell fraction isolated from density-gradient centrifugation by detecting 
EpCAM or cytokeratins [75-77].  
 
 11 
Despite the choice of technique, all the studies have found that baseline CTC 
numbers amongst the different cancer patients do not correlate well with standard 
measures of tumour mass, or serum protein markers (eg PSA) [78, 79]. This may be 
due to inadequate sensitivity of the technology or an indication that CTC count 
depends on additional biological factors such as the potential for invasiveness or 
tumour vascularity rather than just tumour volume [47].  
 
Whilst prognostic studies have correlated clinical outcomes with a baseline count 
above or below an arbitrary threshold value, one group has followed the dynamic 
change in CTC counts to show that CTC counts in lung, prostate and other cancers 
decline rapidly after the initiation of effective chemotherapy, hormonal therapy or 
targeted kinase inhibition and correlate well with standard measures of tumour 
response, irrespective of baseline levels [44, 45, 79].  
 
Measurement of CTCs during and after curative surgery may identify cases that are 
at risk for disease recurrence. Using the microchip technology used above, Stott et 
al detected CTCs in eight cases of prostate cancer which all dropped to 
undetectable level within 24h of surgical resection [79]. Most studies on colorectal 
cancer surgery have focused on the detection of CEA and/or CK19/20 mRNA using 
RT-PCR [80-82]. The presence or absence of CTCs either pre or intraoperatively 
has been found to have prognostic significance in terms of tumour recurrence [80], 
disease free survival (DFS) and overall survival (OS) [83]. It has therefore been 
suggested that their detection could influence the decision as to whether these 
patients receive postoperative chemotherapy.  
 
However, not all studies have found the presence of mRNA intraoperatively or 
postoperatively to be significant. Wong did not find CK20 mRNA to be related to 
postoperative metastases and Topal did not find peripheral CK20 mRNA expression 
to predict recurrence and once again the sensitivity and specificity of measurement 
techniques are open to criticism [84, 85].   
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1.6	 Mutational	analysis	of	CTCs	
 
One of the reasons underlying our inadequate understanding of how tumour cells 
escape the primary tumour, intravasate, extravasate or how they establish a colony 
in a distant organ may be because despite some success capturing CTCs, 
techniques to isolate them in sufficient numbers and under appropriate conditions to 
carry out molecular studies have been lacking [47, 86]. Molecular profiling of CTCs 
could provide information on their origin from primary or metastatic tumours, provide 
clues to their evolution during cancer treatments and identify targets for therapy.  
 
An example is the clinically relevant detection of epidermal growth factor receptor 
(EGFR) mutations in CTCs from lung cancer patients, which predicts dramatic 
response from EGFR kinase inhibitors [44]. Longitudinal follow-up during continued 
therapy found the emergence of a kinase-inhibitor resistant EGFR mutation that 
coincided with clinical drug resistance, suggesting that serial analysis of CTCs may 
allow the monitoring of molecular evolution and predict resistance to therapy.  
 
A similar example is found in breast cancer, where the molecular evolution of 
tumours has been highlighted by the study of CTCs where some HER2-posititve 
CTCs were found in a patient whose primary tumour was HER2-negative [87]. 
HER2-negative CTCs have also been found to emerge from a HER2-positive breast 
cancer patient subjected to anti-HER2 therapy [88].  
 
1.6.1	 KRAS	and	BRAF	mutations	in	colorectal	cancer	
 
The KRAS gene encodes a small GTP-ase that plays a key role in transducing 
signals from the EGFR to downstream effectors. KRAS mutations are commonly 
found in several types of malignancies including colorectal, lung and thyroid 
cancers. The most common mutations are found in codons 12, 13 and 61 [89]. 
Several studies have shown that tumours carrying any of these mutant forms of the 
KRAS gene are less likely to respond to anti-EGFR antibody therapy [90, 91]. New 
studies have also shown that metastatic colorectal tumours carrying mutations in 
exon 4 of KRAS (codons 117 and 146) are less responsive to EGFR inhibitors [92]. 
Other recent studies have shown that not all metastatic colorectal cancer patients 
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with wild-type KRAS tumours respond to anti-EGFR therapy. This suggests that 
additional genes and/or pathways may be involved in the mechanism of resistance 
to these drugs. Mutations in BRAF, another downstream effector of the EGFR-
activated pathway, have been identified in up to 8% of colorectal tumours and their 
expression in tumours has correlated with resistance to anti-EGFR therapy [93-95]. 
Those same individuals also had decreased progression-free and overall survivial 
when treated with EGFR antagonists. 
 
These findings therefore suggest that the ability to detect KRAS mutation in CTCs 
may be able to guide the use of anti-EGFR therapy, a form of ‘liquid biopsy’ that 
might negate the need for a tissue biopsy. 
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1.7		 Aims	and	objectives	
 
The aim of this study was to assess whether a novel and compact filtration device 
could be used in a clinical setting to capture and isolate CTCs from patients with 
metastatic colorectal cancer and perform mutational analysis to identify their KRAS 
mutation status. 
 
The objectives of the study were to: 
 
1. Capture intact CTCs from the peripheral blood of patients with metastatic 
colorectal cancer  
2. Maximise number of CTCs that can be captured from a clinically appropriate 
volume of blood  
3. Perform mutational analysis on captured CTCs and correlate these results 
with those found in tumour tissue  
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Chapter 2	
 
 
 
 
 
 
 
 
 
Materials and Methods 
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2.0	 Materials	and	Methods	
	
2.1	 Materials		
 
Blood samples and tissue were obtained from patients undergoing liver surgery at 
the Royal Surrey County Hospital or receiving chemotherapy at St. Luke’s Cancer 
Centre, Guildford.  
 
HT29 and T-24 cancer cells were used as positive controls for determining the 
appropriate antibodies and dilution to use in identifying CTCs in patient samples. 
HT29 is a human colorectal adenocarcinoma cell line and T-24 a human bladder 
carcinoma cell line. HT29 and PC3 (prostate cancer cell line) were used in spiking 
experiments to determine capture rate and in harvest experiments.  
 
2.1.1	Cell	culture	and	handling	of	artificial	cell	lines	
 
Cells were grown in RPMI media (Sigma-Aldrich) supplemented with 2mM 
GlutaMAX-1 supplement (Invitrogen), 100 units/ml penicillin and 100 units/ml 
streptomycin (Sigma) and with 10% foetal calf serum (FCS). All cell culture work 
was carried out in a sterile environment using a laminar flow hood with a double 
HEPA filter. Passage of cells was carried out when cells approached confluence 
(roughly every 3-7 days depending on the cell line). Cells were washed with Hanks 
Balanced Salt Solution (HBSS, Life Technologies) to remove any foetal calf serum 
and then 0.05% trypsin (Sigma-Aldrich) was added. Once cells were mobile in the 
medium, fresh medium containing foetal calf serum was added to stop the 
trypsinisation. The suspension was then centrifuged at 1500 rpm for 3 minutes and 
the cell pellet resuspended in the appropriate medium and a portion instilled into 
fresh medium. Cells were incubated at 370C.  
 
2.1.2	 Collection	and	handling	of	blood	samples		
 
All blood samples were obtained from consenting patients in a sterile manner and 
using equipment in accordance with Royal Surrey County Hospital trust policy (REC 
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Reference 10/H1109/48). Intra-operative peripheral blood samples were collected 
using intra-venous or intra-arterial lines to avoid epithelial cell contamination of 
samples upon piercing the skin. The consultant surgeon performing the operation 
collected intra-operative hepatic vein samples. Volumes ranging from 2ml to 30ml 
were collected in EDTA containing vacutainers and transported immediately to the 
lab where they were placed on a rocking machine to minimize clotting prior to 
processing. For the capture of CTCs in the Parsortix machine, samples were 
processed within 2 hours whenever possible. 
 
2.1.3	 Parsortix	CTC	capture	and	harvest	machine	
 
The Parsortix machine is a prototype device created by Angle PLC to capture and 
harvest CTCs from fresh blood. It consists of a disposable cassette (same width and 
length as a microscope slide) that contains a micro-filter through which only 
components less than 8µm in size can pass whilst larger components including 
large white blood cells and tumour cells are retained within the cassette.  
 
 
Figure 2.1 Parsortix cell capture and harvest machine. 
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Figure 2.2 The disposable cassette containing the microfilter system on which 
tumour cells are captured 
 
 
Figure 2.3 Schematic of the disposable cassette illustrating the filter mechanism.  
 
The captured cells can be fixed and stained within the cassette to allow in-cassette 
identification and enumeration using fluorescent microscopy or they can be 
recovered using a “HARVEST” function to allow DNA extraction and mutational 
analysis.  
 
The Parsortix system is CE marked for use as an in-vitro diagnostics device in the 
EU and is FDA approved in the United States for research purposes.  
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2.1.4	 Cytokeratin	20		
 
Cytokeratin 20 is a relatively new polypeptide whose expression is almost entirely 
limited to the gastric and intestinal epithelium, urothelium and Merkel cells [96, 97]. 
It is a type 1 CK but with much less acidic properties than the others. Hence there is 
much less cross-reactivity and monoclonal antibodies that would normally broadly 
recognize several intermediate filament proteins do not recognize CK20. Similarly, 
monoclonal antibodies specifically designed to recognize CK20 would be very 
specific.  
 
When tested across a variety of tissues, CK20 expression was not found in smooth 
muscle, blood-vessel walls, lymph nodes or tumour stroma, where other simple-
epithelial CKs are occasionally expressed [98, 99]. 
 
CK20 has been found to be strongly expressed in primary and metastatic colorectal 
carcinomas with strong immunohistochemical staining both in well-differentiated 
tumours and in tumours with dissociated or anaplastic growth patterns [96]. In Moll’s 
landmark study 97% of colorectal adenocarcinomas had some expression of CK20 
[100]. Only 3 undifferentiated carcinomas (solid or signet-ring cell carcinomas) were 
completely negative for CK20. Since then stomach, gallbladder and bile duct 
carcinomas have also been found to be heterogeneously positive.  
 
Moll also found that expression of this CK is a key feature of a few specific 
pathways of epithelial differentiation and despite disturbances of gene expression 
occurring in tumour cells, CK20 continues to be synthesized in the corresponding 
carcinomas and even in their metastases. This was particularly true of Merkel cell 
carcinoma and colorectal carcinoma [100, 101]. Therefore CK20 is thought to be an 
excellent marker for tumor cells arising from the colon.  
 
2.1.5		 CDX2	
 
CDX2 is a homeobox gene involved in the development and differentiation of the 
intestines. Direct evidence of its role has come from studies of transgenic mice 
engineered to express the transcription factor in gastric epithelial cells. Almost all of 
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the gastric mucosa was converted to intestinal cells acidic-type mucins, enterocyte-
like cells and enteroendocrine-type cells [102, 103]. In humans, the transformation 
of squamous-cell mucosa into adenomatous mucosa (intestinal metaplasia) within 
the stomach and oesophagus is consistently accompanied by CDX2 expression 
[102-106]. Hence, CDX2 expression is thought to be a specific marker for epithelial 
cells and neoplasms from the GI tract with selective staining of colorectal and 
duodenal adenocarcinomas observed by using monoclonal antibodies targeted to 
CDX2 [107-109]. 
 
Kaimaktchiev et al carried out CDX2 staining on a series of microarrays totaling 
4652 samples of colon adenocarcinoma of varying stages and grades [110]. They 
found nearly all samples of colon adenoma contained positive staining (97.9%). In 
adenocarcinomas of the colon and rectum 85.7% were positive for CDX2. Whereas 
in the adenomas nearly all of the staining was restricted to the nucleus, in 
adenocarcinomas cytoplasmic staining was evident. Colonic mucinous 
adenocarcinoma was also positive to CDX2 in 81.8% of cases but single examples 
of medullary and neuroendocrine carcinomas that primarily arose in the colon were 
negative. Matched samples of primary and lymph node metastases were 
concordant in 80% of cases for CDX2 expression and all colorectal metastases 
examined were CDX2 positive. Hence, its use can be supported in the identification 
of metastatic tumour cells.  
 
Few other tumours including intestinal-type adenocarcinoma of the stomach 
(28.9%), diffuse-type carcinomas (11.5%) and endometrial adenocarcinoma of the 
ovary were positive to CDX2 but at much lower frequency. Unexpectedly it was also 
found that adenocarcinomas of the pancreas and gallbladder were also negative or 
had very little expression of CDX2, whereas CK20 was much more variably 
expressed. A wide variety of other tumours including oesophageal 
squamous/adenocarcinomas, cervix, kidney, lung and liver hepatocellular 
carcinoma were entirely or almost entirely negative for CDX2, a finding confirmed by 
other studies. Hence, CDX2 is considered a highly sensitive and specific marker for 
colorectal adenocarcinoma.  
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2.1.6	 Antibodies	and	nuclear	stains	used	for	staining	captured	cells	
 
The following antibodies and nuclear stains were used at various points during the 
study for identification of CTCs captured from patient samples. 
 
 Isotype, manufacturer and product code Dilution 
Primary antibodies 
Anti-CK20 Rabbit AbCam Ab76126 1:50 
Anti-CDX2 Rabbit AbCam Ab76541 1:50 
Anti-CD45 Mouse AbCam Ab8216 1:10 
Secondary antibodies 
Alexa-Fluor 488 goat anti-rabbit Invitrogen A11034 1:200 
Alexa-Fluor 546 goat anti-mouse Invitrogen A21123 1:200 
Nuclear stains 
PI (Propium Iodide) 
DAPI (4',6-diamidino-2-phenylindole) 
TO-PRO3 
 
Table 2.1: Antibodies and nuclear stains used during staining of CTCs  
 
2.1.7	 The	QIAamp	DNA	micro/mini	kits	
 
The DNA extraction micro and mini kits produced by Qiagen allows the isolation of 
DNA from small volumes of samples with a centrifugation-based protocol. The 
samples are placed in a small tube (‘column’) that contains a silica-based 
membrane that specifically binds genomic DNA whilst allowing other contaminants 
to pass through during ‘washing’ steps. The DNA can then be eluted from the 
membrane using nuclease-free water or a buffer provided with the kit.  
 
The volume of sample that can be placed in each column is limited to 100µl and the 
volume in which the DNA is retrieved (the elution volume) is flexible between 25-
100µl, depending on the concentration of DNA required.  
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2.1.8	 The	KRBR-50™	Mutational	Analysis	Kit	by	EntroGen	
 
The KRAS/BRAF Mutational Analysis Kit™ by EntroGen is used for the detection of 
mutations in KRAS exons 2, 3 and 4 as well as the BRAF V600E mutation. It is 
based on allele-specific PCR and uses primers that are 100% complementary to the 
mutant variants of the gene. As most samples will contain a mixture of wild-type and 
mutant variants of the gene, the assay is designed to preferentially amplify the 
mutant DNA even in the presence of mostly wild-type DNA. Probes complementary 
to the mutant gene are tagged with a fluorophore (FAM) and a quencher that 
prevents the fluorescence from being emitted. Upon amplification, DNA polymerase 
cleaves the fluorophore and the quencher from the probe allowing the fluorescence 
signal to increase dramatically once free of inhibition from the quencher. A real-time 
PCR machine detects this fluorescence and provides a Ct value based on the cycle 
at which the exponential growth phase takes place. This Ct value can then be used 
to determine the presence of that specific mutation.  
 
An endogenous gene is also amplified (by a probe tagged with VIC/HEX 
fluorophore) in all samples to ensure that sufficient amount of DNA is available for 
amplification and reliable results.  
 
The assay is able to detect 1% mutation in a background of wild-type DNA as long 
as 10ng of DNA in total is present for each reaction. In practice this requires 10ng of 
DNA for detection of the BRAF mutation or 120ng of DNA to detect 1 of the 12 
KRAS mutations. The DNA is also required at a concentration between 1.11 to 30 
ng/µl.  
 
2.1.9	The	Ampli1TM	Whole	Genome	Amplification	(WGA)	Kit	by	Silicon	Biosystems	
 
The Ampli1™ WGA kit was developed to amplify the total DNA content of a single 
cell. It works in four stages: genomic DNA digestion by an enzyme to generate 
19,046,047 fragments all with the same end on both sides, ligation of a single 
adaptor on both ends of each fragment, a fill in reaction to complement the 
sequence of the adaptor and then amplification of all the fragments (the entire 
genome) with a single, highly specific PCR primer that corresponds to the adaptor. 
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The standard PCR amplification method with a highly specific primer reduces bias 
across the genome and ensures exact replication of both alleles at every cycle of 
amplification. The cycles create an exponentially increasing quantity of DNA and the 
output from the whole PCR amplification process is around 1-2ug of double 
stranded DNA and 5ug of single stranded DNA.  
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2.2	Methods	
 
2.2.1	 Spiking	normal	volunteer	blood	with	a	known	number	of	tumour	cells	
 
During initial experiments to assess effectiveness of the Parsortix machine, a known 
number of tumour cells from a cancer cell line (eg. HT29 or PC3) was inserted 
(“spiked”) into normal volunteer blood. These cells were stained with 
Carboxyfluorescein succinimidyl ester (CFSE) prior to spiking so they could be 
identified after processing was complete.   
 
The following method was used for spiking a known number of cancer cells labelled 
with CFSE into 2ml samples of normal volunteer blood. Cultured HT29 or PC3 cells 
were washed three times by re-suspending and pelleting in fresh media. The 
washed pellet was diluted into 10ml of PBS to decrease the total concentration of 
cells per ml. The number of cells per ml was counted using a haemocytometer and 
diluted to approximately 1 x 104 cells per ml. Two microliters of 5mM stock CFSE 
solution was added to 1ml of this solution and mixed by pipetting. This was 
incubated at 370C for 10 minutes before the staining was quenched by adding 5ml 
of ice-cold media to the cells and incubating on ice for 5 minutes. The cells were 
then pelleted and re-suspended in 10ml of fresh media before pelleting and re-
suspending a further 2 times, to total 3 washes. In order to calculate the volume of 
solution containing the required number of CFSE labelled cells, the following 
calculation was used:  
 
 Volume (µl)  = No. of cells required      x 1000 
    Total number of cells  
in 1ml of PBS solution 
 
This volume was collected by a pipette and added to 2ml of whole blood from a 
normal volunteer and mixed by pipetting up and down several times. 
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2.2.2	 Staining	for	adherent	cells	during	development	of	CTC	staining	protocol	
 
In order to determine the correct antibodies and concentrations to use in staining for 
CTCs in patient samples, the following method was used.  
 
Cultured HT29 or PC3 cells were diluted to an approximate concentration of 1 x 104 
cells per ml as above and a drop was placed onto a microslide and allowed to air 
dry. Once dry, 4% Paraformaldehyde (PFA) was pipetted onto this area and 
incubated for 10 minutes (to fix the cells). The slide was then rinsed 3 times with 
PBS. If permeabilisation of the cells was required then 300µl of Phosphate buffer 
saline (PBS) + 0.2% Triton X was added and incubated for a further 10 minutes 
before rinsing 3 times with PBS. The slide was then incubated for 20 minutes in 5% 
normal serum in PBS (this suppresses non-specific binding of IgG). This agent was 
then removed by rinsing with PBS before placing the primary antibody solution (of 
varying concentration) onto the cells and incubating either overnight at 40C or for 1 
hour at room temperature. The slide was then washed 3 times with PBS before 
placing 200µl of fluorescent conjugated secondary antibody onto the cells 
(concentration between 1-10ug/ml in PBS-Bovine Serum Albumin (PBS-BSA)) and 
incubating at room temperature for 45 minutes. The slide was then washed 3 times 
with PBS and mounted with Vectashield before a cover slip was placed on top.  
 
2.2.3	 Collection	of	blood	from	patients	
 
In patients with metastatic colorectal cancer, blood was collected from a peripheral 
vein during their visit to see an Oncologist at the Royal Surrey County Hospital’s 
cancer centre. Initially just 2-5ml of blood was collected and processed. If they were 
found to contain greater than 5 CTCs in a 2ml sample of whole blood, they were 
invited to attend the University of Surrey’s Faculty of Health and Medical Sciences 
department where a larger volume of blood, typically 20-30ml was collected for 
further analysis.  
 
In patients undergoing surgery, 10ml of peripheral blood was obtained on the 
morning of the operation prior to surgery. Intra-operative blood samples were further 
obtained at 2 time-points during surgery. Firstly, when the surgeon was ready to 
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start the resection of the liver parenchyma and again when the division of the liver 
parenchyma was almost complete and the specimen was about to be removed. At 
both time points 10ml of peripheral blood is taken from the arterial line and at the 
same time 10ml of blood is taken from the hepatic vein that is draining the segment 
of liver containing the tumour(s).  
 
2.2.4	 Processing	blood	samples	using	ParsortixTM	
 
2.2.4.1			 Capture	of	cells	using	Parsortix	
 
Prior to processing samples, each machine underwent a cleaning and priming 
programme. Either small volumes (typically 2ml) of whole blood samples or larger 
volumes (5-10ml) of samples with clotting factors and platelets removed were 
inserted into the inlet of the machine. From here, all samples were processed using 
the “SEPARATION” programme of the machine that captures CTCs and other larger 
components of blood in the disposable cassette containing the microfilter. This step 
can take between 2 and 8 hours depending on the type and volume of solution 
being processed.  
 
2.2.4.2		 Identification	of	CTCs	in	spiked	experiments	
 
In spiked experiments, where a known number of CTCs were dissolved into a 
volume of healthy donor blood, cells were labeled with the fluorescent cell staining 
dye CFSE prior to insertion into donor blood. These cells were directly visualized 
after capture by examining the cassette with a fluorescent microscope without need 
for further staining.  
 
2.2.4.3		 Identification	of	CTCs	in	patient	blood	
 
During experiments with patients’ blood, captured cells were stained after capture 
using specific antibodies to selectively identify CTCs. A staining protocol was 
developed to stain captured cells with the necessary antibodies and fluorescent 
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stains to differentiate tumour cells from other blood components. The development 
of this protocol is explained more fully in chapter 3.  
 
Once a staining protocol was developed, a “STAIN” programme was created for the 
Parsortix machine in collaboration with Angle PLC so that cells captured within the 
disposable cassette could be automatically stained with the necessary reagents 
when the volume of patient blood had been processed. Hence, once the 
“SEPARATION” step was completed, the “STAIN” programme was selected by the 
user. During this “STAIN” programme, the cassette was first washed with 4% 
paraformaldehyde to fix the cells and incubated for 10 minutes. Following a rinse 
with PBS, the primary antibodies were added to the cassette (combination of anti-
cytokeratin 20, anti-CDX2 and anti-CD45, see table 1 for isotypes and dilutions) and 
incubated for 60 minutes. After further rinses with PBS secondary fluorescent 
antibodies were added (Alexa-fluor 488 and Alexa-fluor 546) and incubated for 45 
minutes. Following a further rinse with PBS, Vectashield was added for 10 minutes 
to prevent photo-bleaching of the fluorescence. Nuclear stain was introduced either 
as part of the vectashield (Vectashield with 4’, 6-Diamidino-2-Phenylindole (DAPI), 
Vector Laboratories) or as TO-PRO-3 mixed with the secondary antibodies.  
 
Stained cassettes were then examined under fluorescent microscopy or by confocal 
microscopy to determine the number of CTCs. In order to be considered a CTC, a 
cell had to meet the following criteria 
 
1. circular or oval in shape 
2. larger or similar in size to surrounding white blood cells 
3. contain nuclear staining 
4. show positive staining to CK20 +/- CDX2 
5. do not show staining by CD45 (a marker for leukocytes) 
 
2.2.4.4		 Harvesting	of	captured	cells	
 
Cells captured in the Parsortix disposable cassette can be retrieved in a small 
volume of PBS using the “HARVEST” function. In essence, this programme washes 
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the cassette in the reverse direction so that cells caught by the filter mechanism are 
released and redirected into a collection tube through which they can be collected. 
A modification of the harvest programme was to retrieve cells by applying pulses of 
wash. Applying 21 pulses of 10µl PBS in the reverse direction could collect the 
majority of captured cells. 
 
Of practical importance is that captured cells that are stained within the cassette 
cannot then be harvested. Therefore if downstream analysis of harvested cells 
depended on the number of CTCs captured, 2 samples of equal volume had to be 
processed with one sample being stained to enumerate the CTCs and the second 
sample harvested with an assumption that there would be an equal number of CTCs 
as in the stained sample.  
 
2.2.5	 Mutational	analysis	
 
2.2.5.1		 Extraction	of	DNA		
 
Once the captured cells within the disposable cassette were retrieved using the 
“HARVEST” function, DNA extraction was performed using QIamp DNA Micro Kit™ 
according to the manufacturer’s instructions. As the volume of sample that can be 
inserted into each column is limited to 100µl, to obtain the highest concentration of 
DNA that would originate from tumour cells and not from contaminating white blood 
cells, we selectively collected that part of the harvest volume which contained the 
most number of tumour cells (see Chapter 5) in approximately 90-100µl of PBS.  
 
2.2.5.2		 	Measuring	quality	and	quantity	of	extracted	DNA	
 
DNA quality and quantity was assessed by placing 1.2 to 2µl of the eluted solution 
onto a spectrophotometer. As DNA absorbs light at a wavelength of 260 nm (as 
does nucleotides and RNA), the 260/280 absorbance ratio was measured as an 
indication of the purity of DNA. A ratio around 1.8 is generally accepted as a “pure” 
sample of DNA whereas a ratio, which is significantly deviant from this ratio, might 
indicate that the sample is contaminated with protein, phenol or other contaminants, 
which absorb light strongly at or near 280 nm.  
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The 260/230 absorbance ratio is a secondary measure of purity. A value between 
2.0 and 2.2 is accepted as “pure” samples. If the ratio is appreciably lower than this 
range, it may indicate the presence of contaminants that absorb light at wavelengths 
close to 230nm.  
 
2.2.5.3.		 Testing	for	KRAS/BRAF	mutations	using	the	KRBR-50™	kit	by	Entrogen	
 
The minimum quantity of DNA required per reaction using the KRBR™ kit is 10ng. 
The maximum volume of solution in which this DNA can be inserted is 9µl. 
Therefore the minimum concentration of DNA required is 1.11ng/µl. The maximum 
concentration of DNA allowed is 30ng/µl. Therefore if the concentration of DNA is 
greater than this, it needs to be diluted to a usable concentration.  
 
Prior to starting the reactions, all primer/probe mixes, positive control mix and 
reaction master mix were removed from -200C storage and thawed on ice. Each 
reaction chamber contained 30µl in total and consisted of the following: 
  
 2 x PCR reaction mix  15µl 
 Primer mix    6µl 
 DNA sample    10-30ng (up to 9µl) 
 Molecular grade water   adjust to total 30µl 
 
 
Depending on the number of reactions required to detect a mutation (1 in the case 
of BRAF, 12 in the case of KRAS) a sample master mix was made up for each 
patient (with a 5% overage to cover losses during pipetting and transfer) of the PCR 
reaction mix, DNA sample and molecular grade water. After thoroughly mixing this 
master mix by vortexing and centrifuging, 24µl was applied to each reaction 
chamber on a 96-well PCR plate. The appropriate primer/probe mix for each 
reaction chamber was then added (6µl) to complete the constituents.  
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The 96-well plate setup for detecting KRAS mutations is shown below 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Placement of samples and primer/probe mixes for carrying out PCR 
reaction in a 96-well plate for 6 patient samples 
 
The plate was then sealed with optical sealing film and briefly centrifuged to remove 
air bubbles before being placed in a PCR machine. A comparative quantitative 
experiment was carried using the PCR machine by measuring the amount of 
fluorescence emitted from each reaction chamber during subsequent cycles of 
heating to 950C and cooling to 600C. A total of 40 cycles was performed during 
which time 2 types of fluorescence levels were detected. The thermo-profile used in 
the setup of the thermocycler is given below: 
 
 
 
 
  
Table 2.2: Thermo-profile of the thermocycler used for PCR reaction. 
     
Temperature Time Cycles 
95°C 10 min X1 
95°C 15min 
X40 
60°C 60sec 
 31 
The 2 standard fluorescence used in the kit were FAM and VIC which emit light at a 
wavelength of 518 nm and 554 nm respectively. In our PCR machine we did not 
have the filter to measure VIC and therefore used the HEX filter that measures light 
emitted at a wavelength of 556 nm. This was discussed with the manufacturers who 
felt there should not be any significant effects on the data retrieved and the results 
obtained.  
 
The PCR software automatically calculates the Ct value for the HEX and FAM 
fluorescence as the number of cycles at which the exponential growth phase of 
fluorescence occurs.  
 
As described by the manufacturers of the kit, to assess whether a mutation was 
present, one looks first at the calculated Ct value for the HEX fluorescence. If this is 
between 25 and 30, then there was adequate DNA in the reaction and one can 
proceed to examining the Ct value for the FAM fluorescence. If however, the value 
is less than 25, then there is too much DNA and the sample must be diluted to a 
lower concentration and the reaction repeated. If the Ct value is greater than 30, 
then there is insufficient DNA and the amount of DNA inserted must be increased 
and the reaction repeated. This is summarized in the table below: 
  
Table 2.3: Ct value parameters for effective analysis. 
 
If HEX/yellow Ct is: Analysis Description Action 
Between 25 and 30 Ideal Ct range Continue to analyse 
FAM Ct 
Below 25 Overloaded reaction Dilute DNA and re-test 
Above 30 Insufficient DNA Increase the DNA input 
per reaction and re-test 
Not present One of the reaction 
components or DNA 
was not added correctly 
The tests for this 
particular sample has 
failed, don’t continue 
with analysis. 
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If the reaction’s HEX Ct is between 25 and 30, then one can examine the Ct value 
of the FAM fluorescence to determine the presence of that specific mutation. A Ct 
value of 38.5 or lower indicates a positive result (ie. mutation is present). Whereas a 
Ct value above 38.5 or a lack of value indicates that the mutation was not present. 
This is summarized in the table below:  
 
If FAM/green Ct is: Mutation Status 
38.5 or lower Positive 
Above 38.5 or no signal Negative 
 
Table 2.4: Ct values indicating positive or negative results 
 
The manufacturers state that due to cross-reactivity and spillage of fluorescence to 
adjacent reaction chambers, some samples may have positive signals for multiple 
mutations. In such cases, the sample is positive only for the mutation that 
corresponds to the reaction with the most prominent signal (ie. the lowest Ct value). 
 
2.2.5.4		 Ampli1™	Whole	genome	amplification	of	intact	cells	
 
During each run of the WGA kit, eight samples with a negative control (1µl sterile 
PBS) and a positive control (1µl of DNA 1ng/µl) were processed. During samples 
preparation, the negative control (sterile water) was prepared first and the positive 
control (provided with the kit) prepared last to avoid contamination and false results. 
 
All the steps were performed inside a clean laminar flow safety cabinet. All 
instruments including pipettes were cleaned with 70% Ethanol (EtOH) prior to use. 
 
The full protocol for whole genome amplification of intact cells and the constituents 
of each mixture are given in appendix 1.  
 
Basically, a “Lysis Reaction Mixture” is prepared and added to each of the 10 
sample tubes (8 patient samples, 1 negative control and 1 positive control) before 
being incubated for a total of 90 minutes at varying temperatures. A “Digestion 
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Reaction Mix” is then prepared and added to these samples and further incubation 
is carried out for 10 minutes. A “Ligation Reaction Mix” is prepared separately and 
added to each sample with incubation at varying temperatures over 1 hour. Finally 
the PCR reaction constituents are added and 35 cycles carried out using the 
manufacturer’s parameters to obtain the final amplification product.   
 
This product can then be assessed to ensure that adequate quality of DNA from 
intact cells has been amplified using the Ampli1™ QC kit (purchased separately). 
This is a PCR based assay specifically designed to evaluate the output product from 
the Ampli1™ WGA Kit. It assesses whether the amplified DNA was from intact cells 
or from contaminating fragments of DNA. It simultaneously amplifies four different 
genomic targets within the WGA product as well as in a negative control sample and 
a positive control sample. 
 
As instructed by the manufacturer, a reagent mix is prepared for each sample by 
adding sterile water, reaction buffer, PCR deoxynucleotides (dNTPs), QC Primer 
Mix, PCR BSA and Taq polymerase. This mixture is added to each of the test 
samples and the kit’s internal negative and positive control samples. Each tube is 
then mixed by vortexing and samples are incubated in a thermocycler at varying 
temperatures for a total of 34 cycles (see Appendix 1 for full details of volumes and 
thermal settings). 
 
To evaluate the results of the PCR reaction, gel electrophoresis is performed on a 
1.2% Agarose gel. To indicate that the amplified DNA was obtained from intact cells, 
amplification at 4 target locations should be present. Three of these will be single 
bands (at 91bp, 299bp and 614bp) with the fourth a polymorphic band (meaning it 
could be a single or double band) within the region of 108-166bp. The 
manufacturers indicate that for gene specific assays (as with this study) samples 
with 1-2 out of the 4 markers can be used, whereas for genome wide analysis (eg. 
with comparative genomic hybridization) 3 or 4 bands should be present.  
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3.0		 Development	of	protocol	to	isolate	CTCs	using	Parsortix	
 
3.1	 Introduction		
 
As described above “Parsortix” is a compact micro-filtration device that was 
designed by Angle PLC for the purpose of capturing intact CTCs from whole blood 
and retrieving (“harvesting”) them for further analysis. At the start of this study, the 
machine was still in prototype phase and undergoing testing. Alongside our labs at 
the University of Surrey there were also tests being carried out at the Patterson 
Research Institute in Manchester where experiments had been performed using 
spiked cells labeled with the cell staining dye carboxyfluorescein succinimidyl ester 
(CFSE), which had shown promise in capturing and harvesting cells. However the 
capture of CTCs from patients had not been performed.  
 
The machine was designed to capture cells from whole blood by allowing red blood 
cells and other components to flow through the filtration cassette whilst retaining 
cells larger than 8µm. Only small volumes of whole blood (2ml) could be processed 
at a time because a low velocity of flow was required through the micro-filter for it to 
capture the cells effectively, during which time the remaining blood would be 
stagnant in the container (a vacutainer tube). Stagnant blood will start to coagulate 
and form clots and therefore unless all of the blood sample could be processed 
within a short space of time (typically 90-120 minutes), then micro-clots would be 
introduced into the system and cause it to stall due to obstruction.  
 
The first objective was to develop and optimize a protocol for the capture and 
identification of circulating tumour cells from patient samples. In part due to the 
source of funding for this research and in part due to ready availability of clinical 
samples, the main patient groups tested were colorectal patients undergoing 
surgery for liver metastases and colorectal patients with metastatic disease. 
 
The most feasible method of identifying CTCs in patient samples was through 
immunohistochemical staining. However, a general intracellular stain such as CFSE 
 36 
(used in spiked experiments) could not be used for this purpose as all captured 
cells, whether tumour cells, leukocytes or otherwise, would show uptake. It was 
necessary to use antibody stains that would specifically bind to the cells of interest 
(ie. colorectal CTCs). For this purpose, a new staining protocol had to be developed 
consisting of fluorescently labeled antibodies that could be applied to all the cells 
captured by Parsortix, which would then be examined under fluorescent microscopy 
to identify those cells that showed appropriate staining with the relevant antibodies 
to confirm they are colorectal CTCs.  
 
The objectives during this phase of protocol development and testing of Parsortix 
were: 
 
1. Determine the capture efficiency of Parsortix using pre-labelled CTCs spiked 
into whole blood 
2. Optimise the combination and concentrations of antibodies to identify un-
labelled colorectal CTCs within spiked samples 
3. Perform testing on patient samples to identify colorectal CTCs 
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3.2.	 Determination	of	capture	efficiency	using	spiked	samples		
 
The purpose of performing spiked experiments was to confirm that Parsortix was 
capable of capturing tumour cells and to estimate what percentage of tumour cells 
within the sample it was able to capture i.e. the capture efficiency. Whole blood 
samples were obtained from normal volunteers and were spiked with a known 
number of tumour cells from a cancer cell line such as HT29 or PC3. These cells 
were labelled with CFSE and uptake of the fluorescence checked by microscopy 
prior to mixing with whole blood samples. The full method for spiking a known 
number of tumour cells into normal volunteer blood is given in the Materials and 
Methods chapter. Varying quantities of cells (10, 100 and 500) were spiked into 2ml 
samples of healthy donor blood. These samples were then processed in Parsortix 
according to the manufacturer’s instructions.  
 
Firstly, the “SEPARATION” protocol was initiated to carry the blood through the 
machine and to the cassette containing the micro-filter. Once the blood had passed 
through this filter, 1ml of PBS was used to wash the vacutainer to release any 
remaining cells adherent to the wall of the vacutainer and this volume also passed 
through the filter. The cassette was then gently washed with PBS to remove any 
debris before the “SEPARATION” stage finished.  
 
The cassette was then removed and analysed under fluorescent microscopy. Figure 
3.2.1 shows the typical appearance of spiked cells captured in the cassette when 
viewed under a fluorescent microscope. 
 
For each quantity of cells (10, 100 and 500) spiked into normal volunteer blood, the 
experiment was repeated a minimum of 6 times and the number of captured cells 
recorded. Capture efficiency was calculated as the number of cells captured in the 
cassette divided by the number of cells initially spiked into the 2ml of whole blood. 
The results are summarized in graph 3.2.1. The average cell capture efficiency was 
43% with an overall SD of 3%.  
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Figure 3.1 CFSE labeled cells (HT29) captured from spiked blood samples in the 
disposable cassette and visualised by fluorescent microscopy. 
 
 
 
Figure 3.2 Graph showing percentage of PC3 cells captured after spiking into 
normal volunteer blood. Vertical bars indicate standard error; n indicates number of 
times experiment was repeated.  
 
Although this capture efficiency was lower than other technology in the literature, it 
proved the technology was capable of capturing intact CTCs in spiked samples. The 
simple mechanism of capture based solely on physical characteristics meant little 
chemical disruption would have occurred during the isolation process. If these cells 
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could be retrieved intact they would be suitable for further downstream analysis, in 
particular, mutational analysis. 
 
3.3	 Optimization	of	staining	protocol	for	identifying	CTCs	in	patients	
 
Having confirmed that Parsortix was capable of capturing spiked tumour cells the 
next step was to confirm it could capture tumour cells from patient samples. As 
there was no existing protocol for staining and identifying colorectal cancer cells, it 
was necessary to determine the antibodies that could be used to specifically identify 
colorectal tumour cells amongst the variety of other cells found in blood and that 
may also be captured within the cassette. It was also necessary to determine the 
correct concentrations at which these antibodies should be used.  
 
3.3.1	 Choice	of	antibodies	
 
One of the patient groups intended for study of CTCs were those undergoing liver 
surgery for colorectal liver metastases. Whilst CK 8, 18 and 19 were the commonly 
used antibodies for identification of colorectal cancer cells, there was concern as to 
whether this would be appropriate for this patient group as it was recognized that 
smooth muscle cells, lymph nodes, blood vessels and tumour stroma all of which 
would be displaced into the blood during surgery, may express these cytokeratins 
[98, 99]. 
 
The high sensitivity and specificity of CK20 [96, 97, 100, 101] and CDX2 [108-112] 
for colorectal adenocarcinoma reported in the literature and the clinical significance 
of CK20 cells found during surgery [83] guided the decision to perform optimization 
of these 2 antibodies for identification of colorectal CTCs. An additional benefit of 
using these antibodies was that the pathology department at Royal Surrey County 
Hospital included these in their panel of antibodies for distinguishing colorectal 
tumours, meaning that results from this study on patients’ CTCs could be correlated 
with the pathology department’s findings on tumour tissue.  
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To ensure that non-specific binding of antibodies onto cells was not taking place, 
samples were also tested with an antibody that should not stain colorectal cancer 
cells. The antibody chosen for this purpose was CK7 [62, 64-67]. 
 
3.3.2	 	 Optimising	the	working	concentrations	of	antibodies	
 
The 3 antibodies CK20, CDX2 and CK7 underwent a series of titration experiments 
on cells from cancer cell lines (HT29 and T-24) to determine the ideal 
concentrations for use in identifying colorectal CTCs.  
   
The aims of optimisation were: 
  
i) To test the 3 antibodies on control cell lines known to express their 
corresponding antigen, in order to ensure binding was taking place 
ii) To determine the concentrations for each antibody which would facilitate 
accurate visualisation under fluorescent microscopy whilst avoiding 
excess background fluorescence or non-specific staining  
iii) To determine whether positive staining was membranous or cytoplasmic 
iv) To ensure non-specific binding of antibodies was not taking place 
 
The adherent cell lines HT29 (human colon adenocarcinoma) and T-24 (human 
transitional cell bladder cancer) were used as control cell lines to ensure primary 
and secondary antibodies would bind appropriately. HT29 cells are known to be 
positive to CK20 and CDX2. T-24 cells are known to be positive to CK20 and CK7.  
 
The specific isotypes of primary antibodies tested were rabbit anti-human CK20, 
rabbit anti-human CDX2 and mouse anti-human CK7. Fluorescence-conjugated 
secondary antibodies that were isotype specific to each of the primaries were 
obtained from Invitrogen (See Materials and Methods chapter for full details of 
antibodies used).  
 
In order to find the ideal concentration for use with each primary antibody, various 
concentrations were obtained for each antibody and used in staining the positive 
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control cell line before addition of the corresponding secondary antibody. The 
protocol followed for staining of these adherent cells is given in the material and 
methods chapter. Permeabilisation was carried out in all staining at this stage to 
ensure that both surface and internal staining could take place.  
 
In order to ensure that non-specific fluorescence staining by secondary antibodies 
was not taking place, a negative control was included for each primary antibody 
tested. Here, a primary antibody would not be included in the staining and only 
secondary antibodies added to the cells.  
	 	
Stained cells were examined under confocal microscopy. According to the intensity 
of fluorescence arising from stained cells, the effectiveness of staining was visually 
graded as either -ve (no staining), 0 (equivocal),1, 2 or 3 with a higher value 
indicating higher intensity and ease of visualisation. The experiment was repeated 
to confirm the assessment. There were no discrepancies in the results.  
 
HT29 
 Dilutions tested Intensity of fluorescence 
CK20 1:25 3 
 1:50 2 
 1:100 1 
 -ve control -ve 
   
CDX2 1:25 1 
 1:50 0 
 1:100 0 
 -ve control -ve 
T24 
CK7 1:25 1 
 1:50 1 
 1:100 1 
 -ve -ve 
   
CK20 1:25 1 
 1:50 1 
 1:100 0 
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 -ve -ve 
 
Table 3.1: Results of optimisation experiments to determine ideal primary antibody 
concentrations. The concentration highlighted in bold was deemed the ideal 
concentration for that antibody. 
 
The working concentrations determined by these experiments were that CK20 and 
CK7 would be used at a concentration of 1:50 (as the higher concentration of 1:25 
gave excess background fluorescence that would interfere with analysis). CDX2 
would be used at a concentration of 1:25.  
 
3.3.3	 Determination	of	internal	versus	surface	staining	
 
Another series of stains were carried out to see whether antigen-antibody 
conjugation was occurring on the surface of cells or within the cytoplasm of cells. 
For this experiment, some stains were carried out with permeabilisation of the target 
cells (which would allow both surface and cytoplasmic staining to occur) and others 
without permeabilisation (which would allow only surface staining to occur). 
Photographs taken during the experiment are shown in Figure 3.3.  
 
The results showed that on the colon adenocarcinoma cancer cell line HT29, CK20 
was the best antigen to use, as it was found on the surface of cells (did not require 
permeabilisation), was highly expressed at a dilution of 1:50 and allowed ready 
visualisation under fluorescent microscopy. Although CDX2 was expected to stain 
these cells well, in fact positive staining was only present when cells were 
permeabilised and the antibody was used at a high concentration (>1:25).  
 
Given that one of the end-points of the study was to retrieve intact cells for 
downstream analysis, permeabilisation would not be appropriate and therefore 
CK20 alone was taken forward to identify colorectal CTCs in the initial patient 
samples. Given its high sensitivity and specificity for colorectal adenocarcinoma, it 
was felt that it would meet the requirements for identification of CTCs in this patient 
group. A concentration of 1:50 was chosen as the correct concentration to allow 
ready visualisation under microscopy whilst avoiding background fluorescence. 
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  Figure 3.3: Confocal microscope images (x400) showing results of permeabilised and non-permeabilised staining of 
HT29 and T24 cells with primary antibodies. Cells are identified by a red nuclear stain (propidium iodide) and positive 
antibody staining seen as green fluorescence. If staining only occurs on permeabilised cells then the antigens were 
within the cytoplasm, demonstrating internal staining. If staining occurs on both permeabilised and non-permeabilised 
cells, the antigens were present on the surface and surface staining was demonstrated. Underlined image labels indicate 
the overall assessment as to whether staining occurred on the surface or only with permeabilisation (indicating internal 
staining only) for that cell line. 
 
HT29  
(colorectal adenocarcinoma)  
T24 
 (bladder transitional cell carcinoma) 
CK7 + permeabilisation 
 
CK7 surface staining 
 
CK7 + permeabilisation 
 
CK7 surface staining 
 
CK20 + permeabilisation 
 
CK20 surface staining 
 
CK20 + permeabilisation 
 
CK20 surface staining 
 
CDX2 + permeabilisation 
 
CDX2 surface staining 
 
CDX2 + permeabilisation 
 
CDX2 surface staining 
 
-ve control + permeabilisation 
 
-ve control surface staining 
 
-ve control +permeabilisation 
 
-ve control surface staining 
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3.3.4	 Testing	optimized	samples	on	spiked	samples	
 
Once the antibodies and their ideal concentrations had been determined, they were 
tested on spiked whole blood samples processed using Parsortix. For this purpose 
Angle PLC created a staining protocol (“STAIN”) which could be run after the 
“SEPARATION” stage was finished and CTCs were captured within the cassette. 
During this “STAIN” programme, the machine injects the reagents (antibodies, 
nuclear stain and fixative) into the cassette and allows incubation for the required 
periods of time. The steps in the programme essentially follow the same steps as for 
manually staining cells dried onto a micro-slide.  
 
The results were analysed by fluorescent and confocal microscopy and it was 
confirmed that HT29 cells spiked into whole blood could be captured and stained by 
Parsortix to identify CTCs amongst other cells captured in the cassette.  
 
3.4	 Testing	Parsortix	on	patient	samples	
 
The first patient to be tested on the Parsortix machine was a 67 year-old male (JR) 
with widespread metastasis secondary to hilar cholangiocarcinoma. A biopsy taken 
from one of the liver lesions was shown to be positive for CK20 and therefore, 
despite not being a colorectal cancer patient, it was felt he would be an appropriate 
candidate for testing. JR had also been off standard oncological treatment for 
several months, having been overseas trialing alternative ‘holistic’ treatments for his 
disease as clinicians in the UK felt his disease was incurable. Unfortunately the 
alternative treatments had been unsuccessful and he was admitted to the Royal 
Surrey County Hospital with symptoms of progressive disease.  
 
After obtaining consent, a whole blood sample was collected and 2ml of this 
processed in Parsortix using the “SEPARATION” and “STAIN” programmes. The 
cassette was analysed under a fluorescent microscope. Initially, cells were 
examined under a red filter to allow only structures containing the nuclear stain PI to 
be visualized. When circular structures resembling cells were seen to contain PI, the 
filter was changed to green to see whether these structures were also positive for 
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the membranous stain CK20. Cells were counted as tumour cells if they met the 
criteria of: 
 
1) Circular or oval in shape 
2) Similar or larger in size than surrounding white blood cells (which were 
positive to the nuclear stain but not to CK20) 
3) Positive staining with CK20 
4) Positive staining for the nuclear stain PI 
 
A total of 25 cells were found in the 2ml sample. When a second 2ml sample was 
processed in a similar manner from this patient, 49 cells were counted. After 
fluorescent microscopy, these cassettes were also examined under confocal 
microscopy to confirm the staining. Photographs taken by confocal microscopy are 
shown in figure 3.4. 
 
 
 
Figure 3.4 Confocal microscope images of CK20 positive cells captured from whole 
blood sample of patient JR. Photograph A shows cells under a bright field (ie. white 
light only); B, cells imaged under green fluorescence showing CK20 positivity; C, 
cells imaged under red fluorescence showing positivity to nuclear stain PI; D, 
merged image of the 3 previous photographs.   
 
To rule out false positive results due to secondary antibodies binding non-
specifically with antigens, a negative control was performed. This was a sample 
from the patient that underwent staining without any primary antibodies in the 
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reagents but did include fluorescence-conjugated secondary antibodies. After 
washing the cassette, no fluorescence was identified on the cells, indicating that 
previous samples where fluorescence had been found were true-positive results for 
the presence of the CK20 antigen.  
 
3.4.1			Patients	undergoing	surgery	for	colorectal	liver	metastases	
 
To attempt the capture of CTCs from patients undergoing surgery for colorectal 
cancer, patients being admitted to the Royal Surrey County Hospital for excision of 
colorectal liver metastases were recruited. The majority of these patients already 
had the primary colon tumour resected prior to receiving chemotherapy (6 cycles 
over approximately 3 months). They would then have a period of 6-8 weeks off 
chemotherapy (allowing them to recover from its systemic effects) before 
undergoing liver surgery.  
 
Venous blood samples were obtained at various time points immediately prior to 
and during surgery. In order to obtain blood in close proximity to the tumour, 
samples were taken from the hepatic vein directly draining the lobe of the liver, 
when it was safe to do so.  
 
These blood samples underwent the same processing as above with 2ml at a time 
being analysed using Parsortix’s “SEPARATION” followed by “STAIN” programmes 
and the cassettes analysed under fluorescent microscopy. All samples were 
transported within 1 hour of collection to the laboratories at the University of Surrey 
oncology group where they were processed. All samples completed processing 
within 4 hours.  
 
The photograph in figure 3.6 was captured on the fluorescent microscope by first 
taking a photograph under red fluorescence mode and then another under green 
fluorescence mode. These 2 photos were then merged to produce the image shown 
below. 
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Figure 3.5 Image taken on fluorescent microscope showing white blood cells 
(positive to nuclear stain PI (red) but negative to CK20 (green), PI+CK20-) and a 
tumour cell (positive to nuclear stain (red) and positive to CK20 (green), PI+CK20+) 
 
Whilst in most patients CK20+ cells were rare findings amongst other nucleated 
cells, in some patients, they were much more common. It was noted that this was 
particularly the case where the sample of blood had been obtained intra-operatively 
from the hepatic vein of the liver segment being resected. The photograph in Figure 
3.6 shows such a patient where multiple CK20 positive cells can be seen clustered 
together.  
 
 
 
 
 
 
 
 
 
Figure 3.6 CK20 positive cells found in the hepatic vein blood of a patient 
undergoing liver surgery for colorectal liver metastases. The cells emit green 
fluorescence (CK20) and contain red fluorescence (PI nuclear stain) 
 
Figure 3.7 shows a photograph where an image taken under bright field (ie. white 
light) was combined with images taken under green and red fluorescence to 
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visualise the cassette containing the stained cells. This shows the majority of CK20+ 
cells (white arrows) are captured within the outer step of the filter tracks. 
 
 
 
Figure 3.7 Merged image of photographs taken using green fluorescence, red 
fluorescence and bright field (white light). The majority of CK20+PI+ cells (white 
arrows) are noted to lie along the outside filtration tracks of the Parsortix cassettes. 
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3.5	 Triple	staining	for	immunohistochemical	confirmation	of	tumour	cells	
 
Whilst studies have correlated the presence of CK20 positive cells with clinical 
outcomes, the current accepted standard for immunohistochemical identification of 
CTCs are that cells must not only show positive uptake of a CK specific antibody 
and have positive uptake of a nuclear stain (such as PI, DAPI or TO-PRO-3) but 
they must also be negative towards a leukocyte antigen marker (ie. CD45). It was 
therefore necessary to further develop the staining protocol to include this marker. 
Due to limited availability of differently coloured fluorescence, the nuclear stain used 
in this new combination had to be changed.  
 
In this updated triple staining protocol: 
 
Blue = Nuclear stain; TO-PRO3  
 Green = CK20 
 Red = CD45 
 
In order for captured cells to be identified as a CTC, there was now an additional 
requirement that they should show lack of CD45 antibody uptake: 
 
1) Circular or oval in shape 
2) Similar or larger in size than surrounding white blood cells (which were 
positive to the nuclear stain but not to CK20) 
3) Positive staining with CK20 
4) Positive staining for a nuclear stain 
5) Negative to CD45 
 
Five patients undergoing surgery for colorectal liver metastases had 4 samples 
taken each, 2 before resection of the liver segments (from a peripheral arterial line 
and from a central venous catheter) and 2 during liver resection itself (from a 
peripheral arterial line and either from a hepatic vein or central venous catheter).  
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The number of cells exhibiting CK20 positivity and CD45 negativity (i.e. 
CK20+CD45-) and the number exhibiting CK20 positivity but also CD45 positivity 
(i.e. CK20+CD45+) were counted in each sample. Table 3.3 gives the results 
obtained for all patients and samples.  
 
Although CK20+ cells were a minority amongst CK20- negative cells, almost all of 
the CK20+ cells were also CD45+ (ie. CK20+CD45+) and therefore were not CTCs. 
Figure 3.8 shows a series of photographs illustrating this.  
 
 
 
Figure 3.8 Photographs of the same frame taken under different fluorescence 
modes. A, green fluorescence mode identifying a cell as positive to CK20 (white 
arrow); B, red fluorescence mode identifies the same cell as also positive to CD45 
(the cell adjacent to this (yellow arrow) identifies a white blood cell which is not 
positive to CK20); C, both cells are positive to the nuclear stain TO-PRO-3; D, white 
light shows the cell in question in focus; E, shows the previous images merged 
together.  
 
Only in one patient, in a sample taken pre-operatively from a central venous 
catheter, was there 2 cells that were CK20+CD45- and therefore could be 
considered CTCs (one of these is shown in Figure 3.9). Notably, both of these cells 
A 
E D 
C B 
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were much larger (approximately 40 µm in diameter) than surrounding 
CK20+CD45+ cells.  
Patient No. – 
Sample No. 
CK20+CD45+ cells CK20+CD45- 
cells (CTCs) 
1-1 3 0 
1-2 1 0 
1-3 16 0 
1-4 13 0 
2-1 12 0 
2-2 5 0 
2-3 15 0 
2-4 8 0 
3-1 2 0 
3-2 6 2 
3-3 16 0 
3-4 18 0 
4-1 5 0 
4-2 2 0 
4-3 15 0 
4-4 32 0 
5-1 7 0 
5-2 3 0 
5-3 12 0 
5-4 20 0 
 
 
Table 3.3 CTC counts in samples taken from patients undergoing surgery. Samples 
1 and 2 for each patient were taken pre-operatively, whilst samples 3 and 4 were 
taken postoperatively.  
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Figure 3.9 Photograph of the same cell taken in different fluorescence modes. A, 
green fluorescence showing positivity to CK20; B, red fluorescence showing 
negativity to CD45; C, blue fluorescence shows the cells to contain the nuclear stain 
TO-PRO-3; D, merged image of the above photos.  
	
The conclusion from these results was that these CK20+CD45+ cells were a 
subtype of white blood cells, different in phenotype to the CK20-CD45+ white blood 
cells but not CTCs.  
 
Therefore, it appeared that whilst there were a large number of CK20 positive cells 
which were a subtype of white blood cells, there were not many CTCs in the blood 
of patients undergoing surgery for colorectal liver metastases (even when taken 
from vessels in close proximity to the tumour).  
 
 	
D 
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3.6	 Identification	of	CTCs	in	patients	with	metastatic	colorectal	cancer	
 
 
The second group of patients tested for the capture of intact CTCs using Parsortix 
were those with metastatic colorectal cancer. In these patients, the expected 
number of CTCs would be higher based on the fact that disease is present in more 
than one location and therefore likely to be present in the intravascular 
compartment. However, many of these patients would be undergoing chemotherapy 
(particularly those attending hospital) and this may reduce numbers of CTCs.    
 
In the setting of colorectal cancer patients attending the hospital, this meant 
identifying those patients who were new referrals for consideration of chemotherapy 
or were being reviewed after a prolonged period (6 weeks or more) off 
chemotherapy. Unfortunately only a very few patients matched this criteria and the 
majority of recruited patients did have chemotherapy within the 6 weeks preceding 
collection of the sample.  
 
From these patients, a small volume of peripheral blood was collected and 
processed using the Parsortix “SEPARATION” and “STAIN” programmes. The triple 
staining protocol was used on all occasions and the results analysed under confocal 
microscopy. Only cells found to be both CK20+ and CD45- were counted as CTCs. 
Images taken on confocal microscope were examined by 2 investigators before a 
decision was made to count a cell as a CTC. 
 
The demographics, disease details and CTC counts found in the 10 patients are 
given in Table 3.4. For those patients who had chemotherapy within the last 6 
weeks, this is indicated.  
 
Six of the 10 patients had CK20+CD45- CTCs but using the cutoff of ≥2 CTCs, as 
found in current literature, the detection rate of colorectal CTCs using Parsortix and 
a small volume of blood in patients with metastatic disease is 50%.        
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Table 3.4 Patient demographics, disease history and current disease status of 
patient who underwent testing for CK20+/CD45- CTCs with 2ml whole blood 
sample 
 
 
 
 
 
 
 
 
Patient 
No. 
Age 
(years), 
sex 
Disease History Current disease 
locations 
Chemotherapy 
within 6 
weeks? 
CTC No. 
1. JK 56, 
female 
Previous right hepatectomy for 
colorectal cancer, enlarged lymph 
nodes along right hepatic artery 
Liver and lymph 
nodes 
Yes 0 
2. MD 55, male Left liver lesion found on CT, 
previous Hepatitis C 
Liver No 5 
3. BS 62, male Recurrence post primary sigmoid 
cancer resection. On 
maintenance chemotherapy 
Colon and liver Yes 5 
4. JD 56, 
female 
Recurrence of colorectal cancer in 
colon and lymph nodes 
Colon and lymph 
nodes 
Yes 0 
5. AB 79, 
female 
Caecal cancer with synchronous 
liver metastases, inoperable. 
Colon and liver Yes 1 
6. JP 72, male Inoperable disease in ascending 
colon and liver 
Colon and liver Yes 0 
7. GP 57, 
female 
Recurrence of colon cancer, 
widespread liver and peritoneal 
metastases 
Liver and 
peritoneum 
Yes 2 
8. AA 70, 
female 
Colorectal primary with liver and 
possible lung metastases 
Colon, liver and 
lung 
No 3 
9. LA 68, 
female 
Colorectal cancer recurrence, 
found to be inoperable. 
Underwent palliative procedure 
due to colonic obstruction. 
Colon Yes 4 
10. DS 58, male Recurrent disease in lymph nodes 
peritoneal metastases 
Lymph nodes and 
peritoneum 
No 0 
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3.7	 Discussion		
 
These initial experiments have shown that Parsortix has the ability to capture 
tumour cells in both spiked and patient samples. The capture efficiency was 
determined in spiked samples and was shown to be 43% with an overall SD 
of 3%. This is low compared to other technologies that use microfiltration 
systems, with several recent publications showing a yield between 80 to 98% 
when tested with various cancer cell lines [46]. As the spiked cells were 
stained before insertion into whole blood, the problem of positively identifying 
tumour cells was not a problem with spiked samples as compared to patient 
samples. This capture rate is therefore likely to be accurate for these cell 
lines. However, the experiment was only carried out on 2 cell lines and further 
experiments with a wider range might give a more accurate overall measure 
of yield.  
 
Although less than half of spiked cells were being captured, the fact they 
could be captured with minimal chemical disruption meant that if these cells 
could be retrieved, further analysis would be possible. An advantage of 
Parsortix over some other microfiltration systems is that the mechanism of 
separation is relatively uncomplicated and therefore minimal physical 
disruption occurs to the cells. It also uses a step-wise filtration architecture 
that has not been used before and could potentially minimize cell membrane 
damage by avoiding sudden impact and lodging onto the edges of pores.  
 
During the optimisation process to test patient samples, we tested CK20 and 
CDX2, which were both, expected to be expressed in colorectal 
adenocarcinoma cells. Whilst CK20 was clearly expressed on HT29 cells and 
could be visualised at a concentration of 1:50, CDX2 expression was only 
seen when cells were permeabilised (meaning surface expression was not 
seen) and even here only at a higher concentration of 1:25. Previous reports 
have shown that although CDX2 is restricted to the nucleus in colon 
adenomas there is cytoplasmic expression in adenocarcinomas [110]. 
However, as the HT29 cell line is from a well differentiated (grade I) primary 
 56 
tumour [Sigma-Aldrich product information] it may be that it does not, or has 
minimal, cytoplasmic expression. The very low expression of CDX2 by HT29 
cells has also been found in other studies [113]. The decision to continue 
further experiments with CK20 alone were based on the intention not to 
permeabilise cells during patient experiments and because CK20 positive 
CTCs had been shown to have clinical significance.  
 
We initially tested the antibody staining on several patients undergoing 
surgery for colorectal liver metastases and found CK20 positive cells in the 
majority of samples, with blood samples obtained from the hepatic veins 
showing particularly high numbers [data not shown]. This was surprising given 
the rarity of CTCs normally found in blood samples and reported in the 
literature. It was with the addition of CD45 to the staining protocol and the 
undertaking of analysis with confocal microscope that these cells were 
revealed to be non-neoplastic cells.  
 
The background transcription of cytokeratin genes by non-neoplastic cells 
within a sample, which poses a methodological problem was first shown by 
Chelley and colleagues in 1989 [114] who found it to be problematic during 
RT-PCR detection of CTCs. This has since proven to be the case for almost 
all cytokeratins including CK 8 [115], CK18 [115] and CK 19 [116], the 
commonly used cytokeratins in identifying colorectal cancer cells. Jung et al 
were the first to show that neutrophil granulocytes have a background 
expression of CK20 at the mRNA level [117] and since then the background 
expression of CK20 has similarly been found in other smaller studies with 
about 10% of blood samples from patients undergoing surgery for benign 
conditions containing CK20 mRNA [118-120]. The results found here confirm 
that CK20 cannot be used alone in immunohistochemical analysis of cells as 
there is positive staining of a sub-set of white blood cells.  
 
A higher capture rate of CK20+CD45- CTCs was found when samples were 
obtained from patients with stage III/IV colorectal disease, with 50% of 
samples showing ≥2 CTCs in 2ml of whole blood (median 4, range 2-5). Allard 
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et al. [41] enumerated CTCs (EpCAM+CK8/18/19+CD45-) in a variety of 
cancers using the Cellsearch system and found the average number in 
colorectal cancer patients to be 4±11 cells in 7.5ml of peripheral blood. 
Although they did not specify the stage of disease, the incidence of ≥2 CTCs 
in peripheral blood was 30%. Cohen et al, in their landmark study to look for 
CTCs in a large population of metastatic colorectal cancer patients using 
Cellsearch, found ≥3 CTCs in 108 of 413 (26%) patients [121]. As in our 
study, this was performed on a heterogenous population of patients 
undergoing first, second or third line chemotherapy. The comparable rate from 
the results here would be 40% using the same cut-off.  
 
The capture rate in metastatic colorectal cancer patients using Parsortix is 
therefore similar if not slightly better than the FDA approved CellSearch 
system and might even be higher if more cytokeratins or other markers (eg. 
CDX2) were included alongside CK20. It has been well recognized that a flaw 
of CellSearch is that it relies on the expression of EpCAM to capture cells and 
therefore may produce false-negative results [122]. The lack of reliance on 
EpCAM or other epithelial markers for capture and the relative low cost for 
sample processing might make Parsortix a contender in the market. However, 
larger studies on a more homogenous patient population are needed.  
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Chapter 4	
 
 
 
 
 
 
 
 
 
Maximising the capture of CTCs in 
patient samples 
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4.0	 Maximising	CTC	capture	from	patient	samples	
 
Having identified that a significant percentage of patients with metastatic 
colorectal disease would have CTCs in their peripheral blood, it was 
necessary to maximize the number of CTCs obtained in order to perform 
mutational analysis. Two limitations to capturing more cells were that 
Parsortix was only able to process small volumes of blood and the current 
protocol only identified colorectal cancer cells using a single antigen, CK20. In 
order to increase capture rate, we investigated the addition of further staining 
antibodies and attempted to increase the volume of blood that could be 
processed.  
 
4.1	 Staining	with	CK20	and	CDX2	
 
Consideration was given to trialing a pancytokeratin stain to identify epithelial 
cells but it was felt this would be less specific for cells of a colorectal origin 
and may result in false-positive results. Another option was to find another 
antigen that would have high sensitivity as well as specificity for identifying 
colorectal cancer cells. Following discussions with pathologists at the Royal 
Surrey County Hospital trust and other researchers in the field of CTCs, it was 
decided that including CDX2 alongside CK20 may increase the yield of 
captured CTCs. Pathologists at the hospital felt they had increased their 
sensitivity for detection of colorectal cells in tissue by including CDX2 in their 
staining protocol and published studies had found the same, with CDX2 
having a high sensitivity of 97.9% for detecting cells from the colon and 85.7% 
for detecting colorectal adenocarcinoma cells. [110] Specificity in this instance 
would not be reduced either as it is a marker of epithelial cells derived from 
the GI tract. 
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The staining protocol was modified to include CDX2 alongside CK20 and as 
both antibodies were of the anti-rabbit isotype, the same secondary 
fluorescence labeled antibody could be used to identify them both.   
 
Small volumes of peripheral blood were obtained from patients with metastatic 
colorectal cancer and 2ml from each sample was processed in Parsortix to 
capture CTCs using this new triple staining protocol. The results were 
analysed using confocal microscopy.  
 
These technique was tested on 10 patients with stage III/IV colorectal cancer 
disease. The demographics, operative findings and pathological details for 
these patients are given in Table 4.1 whilst Figures 4.1 and 4.2 show images 
taken using the confocal microscope.  
 
We found that CDX2/CK20+CD45- CTCs could be identified in 9 out of 10 
patients. The results were confirmed by a second assessor examining 
photographs taken in different fluorescence modes and on occasions re-
examining the cassettes under confocal microscopy.  
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Figure 4.1 Photographs of the same cell taken on confocal microscope x400 
magnification. A, taken under green fluorescence showing positivity to 
CK20/CDX2; B, red fluorescence showing negativity to CD45; C, blue 
fluorescence showing positive nuclear staining (TO-PRO-3); D, bright field; E, 
merged photo incorporating all of the above photographs.  
 
A B 
C D 
E 
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Figure 4.2 Photographs of CTCs captured in the peripheral blood of patients 
with metastatic colorectal cancer. Various cells identified using CK20 and 
CDX2 as membranous staining antibodies (green). The intracellular 
components are stained with TO-PRO-3 (blue). There was no CD45 positivity 
(red) in these cells. Images taken on confocal microscope x200 magnification, 
merged filter images. 
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Table 4.1 Demographics, history and disease status of patients tested for 
CK20+/CDX2+ CTCs in 2ml of whole blood.  
* patient had more than one sample tested and therefore mean number of CTCs 
given
Patient  Age, 
sex 
Disease History Previous 
chemo-
therapy 
Current 
disease 
locations 
Currently on 
chemo-
therapy? 
CTC No. 
1. AA 70, 
female 
Metastatic colorectal cancer 
with liver and lung metastases 
Yes Colon, liver and 
lung 
No 2* 
2.CS 60, male Sigmoid colectomy 2 years 
previously, currently 
undergoing chemotherapy 
prior to liver resection 
Yes Multiple liver 
lesions 
Yes 0 
3. LR 52, 
female 
Sigmoid cancer with liver 
metastases. Underwent liver 
resection (primary still in-situ) 
Yes Sigmoid primary No 12 
4. AE 69, male Previous resection for rectal 
tumour and hemi- 
hepatectomy for metachronous 
liver metastases. 
Yes Liver and 
peritoneum 
No >21 
5. FS 62, male Colorectal cancer resected 1 
year previously. Recurrence of 
metastases 6 months later. 
No Liver No 2 
6. NH 56, 
female 
Primary sigmoid cancer with 
liver metastases. 
Yes Colon and liver Yes 1 
7. RH 66, male Caecal cancer resection in 2 
years previously. Recurrence 
of liver metastases. 
Yes Liver Yes 9 
8. CS 38, male Underwent primary colonic 
tumour resection and liver 
resection for metastases 
Yes Liver and 
peritoneum 
Yes 4 
9. JG 74, 
female 
Sigmoid cancer with extensive 
metastases, inoperable. 
No Sigmoid colon, 
liver and lungs 
No 12 
10. AJ 71-year 
old male 
Caecal tumour resected 1 year 
previously, followed by liver 
resection. Has recurrence in 
liver 
Yes Liver Yes 71 
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4.2	 Increasing	the	processing	volume	
 
At the start of the study, it was not possible to process more than 2ml of whole 
blood at a time due to the low speed at which blood needed to flow through 
the filtration mechanism. The long processing time meant the remaining 
stagnant blood would coagulate. Techniques of delaying the coagulation 
mechanisms were already incorporated into the protocol, for example 
collecting and processing blood in an EDTA containing tube, slowing the 
clotting cascade by storing the blood in cooler temperatures and keeping the 
blood on a ‘rocker’ that moves the vacutainer in a circular/swinging motion 
whilst waiting to start the processing.  
 
From early on in the study, several other methods were investigated to 
increase the volume of blood that could be processed, as it was anticipated 
this would be necessary to obtain greater quantities of CTCs. Those methods 
that showed promise were now trialed on patient samples.  
 
4.2.1	 Use	of	a	magnetic	flea	
 
One attempt to slow the onset of coagulation was to use a magnetic stirrer, 
termed a ‘flea’ to keep the blood mobile within the vacutainer whilst waiting to 
be processed during the “SEPARATION” stage. This was combined with 
dilution of whole blood with PBS to avoid lysis of cells. During spiked 
experiments it was found that up to 8ml of whole blood could be diluted with 
2ml of PBS and processed using a magnetic flea without microemboli halting 
the process.  
 
Whilst testing patient samples, 2ml of whole blood was processed and stained 
in the standard way described above and another 8ml was mixed with 2ml of 
PBS for processing with a magnetic flea. 
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The same triple staining protocol was used in both cases and the cassettes 
analysed using confocal microscopy. The 2ml cassette of each patient 
underwent analysis first and if this contained 1 or more CTCs, indicating the 
presence of CTCs, then the corresponding 8ml cassette was analysed. The 
results for those patients who underwent analysis of both cassettes are shown 
in Table 4.2. 
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Table 4.2 Details of patients that underwent testing for CTCs in 2ml and 8ml 
samples with the use of a magnetic flea and dilution in PBS 
Patient  Disease  Staining 
reagents/ 
antibodies 
2ml 
CTC 
Number  
Magnetic 
flea 
speed 
Time for 
“SEPARATION” 
of 8ml sample 
8ml 
CTC 
Number 
Conta-
minating 
cells 
Debris 
1. MD Previous resection of 
rectal tumour and 
liver metastases. 
Recurrence in liver.   
DAPI, CK20, 
CD45 
5 300 rpm Not recorded 0 ++ ++ 
2. BS Recurrent sigmoid 
cancer  
DAPI, CK20, 
CD45 
2 300 rpm Not recorded 0 ++ ++ 
3. LA Recurrent colon 
cancer with 
metastases 
DAPI, CK20, 
CD45 
4 200 rpm Not recorded 0 ++ +  
4. AB Sigmoid cancer with 
liver metastases, 
inoperable 
DAPI, CK20, 
CD45 
26 300 rpm 5hr 30 0 ++ ++ 
5. GP Liver metastases 
recurrence 3 years 
post resection 
DAPI, CK20, 
CD45 
2 200 rpm 5hr 50 0 + No 
6. AB Sigmoid cancer with 
liver metastases  
DAPI, CK20, 
CD45 
2 200 rpm 4hr10 0 + + 
7. AA Colorectal primary 
with liver and 
possible lung 
metastases on CT 
DAPI, CK20, 
CDX2, CD45 
1 200 rpm 6hr 40 0 + + 
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Despite obtaining results with spiked samples, there were no intact tumour 
cells found within these patient samples, only an abundance of CD45+ white 
blood cells. The typical appearances of these cassettes are shown in figure 
4.3. There appeared to be a lot of debris amongst white blood cells. There 
was also evidence of fragmentation of cells that were positive to CK20 or 
CDX2 (Figure 4.4) that may have been CTCs but were damaged during the 
separation process or afterwards. Fragmentation seemed to be an issue even 
after the velocity of the magnetic flea was reduced from 300 rpm to 200 rpm 
although the amount of debris decreased (Figures 4.3a and 4.3b). When the 
speed of the magnetic flea was reduced further, blood began to clot within the 
vacutainer and the separation process could not be completed.  
 
 
 
 
Figure 4.3 Typical appearance of samples when processed with magnetic 
flea at 300 rpm (A) and at 200 rpm (B), showing several CD45 positive (RED) 
white blood cells in both samples but with less debris (seen as blue or green 
staining in the space between cells) when processed at 200 rpm. 
Photographs taken on confocal microscope, x200 magnification; merged 
images combining green (CK20/CDX2), red (CD45) and blue (TO-PRO-3) 
fluorescence. 
 
A B 
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Figure 4.4 Fragmented cells positive to CK20/CDX2 (green) with intracellular 
staining with TO-PRO-3 (blue) but negative to CD45 (red). Photographs taken 
on confocal microscope, x200 magnification; merged image combining green 
(CK20/CDX2), red (CD45) and blue (TO-PRO-3) fluorescence.   
 
It is possible that the force created by the flea caused physical disruption to 
cells and caused mechanical lysis despite dilution with PBS. It could be 
hypothesised that artificially cultured cell lines on which this technique worked 
are likely to be more robust than the tumour cells found in our patients. As the 
majority of these patients would have undergone chemotherapy during the 
preceding months, this may have contributed to the fragility of tumour cells. 
From our experiments, it appeared that whilst this technique might work with 
artificial cancer cell lines, it was not appropriate for patient samples.  
 
 
4.2.2	 Diluting	blood	with	PBS	
 
This technique involved diluting samples and the clotting factors within them. 
It was found that as samples become less viscous when mixed with PBS, the 
same volume of sample would flow through the machine at a faster rate. It 
was hypothesized that diluting the clotting factors and allowing samples to 
flow through the machines faster, would delay coagulation and allow a greater 
volume to be processed. The ratio of PBS to whole blood was therefore 
increased to 1:1 prior to the start of the “SEPARATION” programme.  
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A comparison was carried out between 2ml samples and 4ml samples taken 
at the same time on 6 patients. The 2ml samples were processed in the 
standard way with just 0.5ml of PBS being added during the “SEPARATION” 
stage (part of the normal protocol) whilst the 4ml samples had an additional 
3.5ml of PBS added (bringing the total volume of PBS to 4ml). The ratio of 
PBS to whole blood in these latter samples was therefore 1:1. In all samples 
the captured cells were stained using the “STAIN” programme and the 
cassettes analysed with confocal microscopy. The results are given in Table 
4.3.  
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Table 4.3 Details of patients that underwent testing of 2ml samples and a 4ml 
sample mixed with 4ml of PBS. In the first 2 patients a magnetic flea was used 
but this was not continued as the same problem of cell fragmentation and debris 
was found in the cassettes. 
Patient 
No. 
Disease Staining 
reagents/an
tibodies 
2ml 
CTC 
Number 
Magnetic 
Flea 
speed 
Time for 
“separation” 
step for 8ml 
sample 
4ml Sample 
+ 4ml PBS 
CTC Number 
Conta-
minating 
cells 
Debris 
1 AB1 Sigmoid cancer 
with liver 
metastases, 
inoperable 
CK20, 
CD45, 
TO-PRO-3 
2 300 rpm 2hr 05 2 Minimal ++ 
2 AB2 Repeat sample 
from patient 1 
taken 2 weeks after 
initial sample 
CK20, 
CD45, 
TO-PRO-3 
2 200 rpm 2hr 40 0 Minimal ++ 
3 AA Colorectal primary 
with liver and 
possible lung 
metastases on CT 
CK20, 
CDX2, 
CD45, 
TO-PRO-3 
1 No 4hr 27 2 ++ + 
4 LR Sigmoid cancer 
with synchronous 
liver metastases. 
Sample taken on 
day of surgery for 
liver resection 
CK20, 
CDX2, 
CD45, 
TO-PRO-3 
12 No 4hr 19 5 + + 
5 AE Recurrence of 
peritoneal and liver 
metastases after 
resection of 
primary colon 
tumour and liver 
metastases. 
CK20, 
CDX2, 
CD45, 
TO-PRO-3 
21 No Not recorded 5 Minimal + 
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Whilst intact cells could be recovered using this technique, there was not an 
increase in number as compared to the increase in whole blood volume. In 
some cases, the number of cells actually decreased with the larger volumes. 
When compared with the previously described technique using a magnetic 
flea, there was generally less contaminating white blood cells although a 
significant amount of debris was still found (see Figures 4.5 and 4.6).  
 
A possible explanation for the lack of effectiveness with this method is that the 
Parsortix machines are constructed to maintain an appropriate velocity for 
filtration to take place and the artificial increase in velocity created by this 
method actually causes less efficient filtration, resulting in more CTCs passing 
through the filter or indeed being destroyed due to greater shear forces. 
 
  
 
Figure 4.5 Typical appearance of cassettes when samples are processed 
using the 4ml whole blood + 4ml PBS technique. An intact 
CK20/CDX2+CD45- cell is seen in the left upper quadrant (white arrow). 
Surrounding fragments stained non-specifically (blue arrows) are debris.  
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Figure 4.6 Photograph of a CTC (CK20/CDX2+TO-PRO+CD45-) (white 
arrow). A, green fluorescence demonstrates positivity to CK20/CDX2; B, 
absent red fluorescence (CD45) indicates this is not a white blood; C, blue 
fluorescence shows positive intracellular staining with TO-PRO-3; D, 
brightfield image showing appearance of the cell under white light; E, merged 
photograph of above images. 
  
4.2.3	 Removing	clotting	factors	-	Patterson	Protocol	
 
A technique that showed promise at the Patterson institute with spiked 
samples was the removal of clotting factors from whole blood samples and re-
suspension of the remaining fraction in a physiological solution (such as 
Hanks’ Salt solution) prior to processing. They found this increases the 
volume of blood that could be processed before micro-emboli became an 
issue, thus increasing the number of CTCs captured.  
 
The described method was followed by taking 10ml of whole blood, 
centrifuging at 2000rpm for 10 minutes to separate the blood components into 
separate fraction and then removing the plasma fraction before resuspending 
A 
E 
B C 
D 
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the red cells and mononucleated cells (which include CTCs) in 5ml of Hanks 
solution. This is then processed using Parsortix.  
 
This protocol was performed on 2 patients who were previously found to have 
a high number of CTCs in their blood. Again a 2ml sample was processed in 
the standard way before being stained and analysed, whilst another 10ml 
sample was processed using the Patterson protocol before being stained and 
analysed. The results are given in table 4.4.  
 
The results showed that when larger volume of blood was processed using 
the Patterson protocol, fewer intact cells were retrieved than in just 2ml of 
whole blood. Once again we concluded that whilst this protocol seemed 
effective on spiked samples, it was not effective for capturing CTCs in patient 
samples.
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Table 4.4 Patient details and results of patients that underwent testing of a 
2ml whole blood sample and another 10ml sample processed using the 
Patterson protocol. 
  
Patient 
No. 
Disease Staining 
reagents/ 
antibodies 
2ml 
CTC 
Number 
Time for 
“seperation” 
Patterson 
protocol 
Patterson 
protocol  
CTC 
Number 
Conta-
minating 
cells 
Debris 
1. LR Sigmoid cancer 
with synchronous 
liver metastases. 
Sample taken on 
day of surgery for 
liver resection 
CK20, 
CDX2, 
CD45, 
TO-PRO-3 
12 3hr 9 4 +/- + 
2. AE Recurrence of 
peritoneal and liver 
metastases after 
resection of primary 
colon tumour and 
liver metastases. 
CK20, 
CDX2, 
CD45, 
TO-PRO-3 
21 3hr 10 4 +/- + 
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4.2.4	 Ficolling:	Isolating	the	mononuclear	cell	fraction	
 
A method of isolating the mononuclear fraction described in previous studies 
was Ficoll-density gradient centrifugation. In this method, whole blood 
samples are diluted with a physiological solution such as Hanks or PBS at a 
ratio of 1:1 and then carefully placed above 10ml of Ficoll density gradient 
solution. This Ficoll solution, due to its higher density, does not readily mix 
with whole blood. However, when centrifuged at a slow speed for a prolonged 
period (600 rpm for 25 minutes), it allows the heavier components of whole 
blood (ie the iron containing red blood cells) to travel through it to collect at 
the base of the vacutainer. The lighter mononuclear cells and CTCs collect 
just above the Ficoll solution and form a thin layer (called the mononuclear 
interphase layer) whilst the lightest fractions such as clotting factors, plasma 
and platelets form the uppermost layer. By carefully extracting the 
mononuclear interphase layer, the white blood cells and CTCs can be isolated 
from the other cell components and then separately processed through 
Parsortix.  
4.2.4.1		 Pelleting	and	re-suspending	mononuclear	cell	interphase	in	PBS	
 
In initial experiments with density gradient centrifugation, the mononuclear 
interphase layer was collected and centrifuged to form a cell pellet, which was 
washed with PBS twice to ensure all clotting factors and red-blood cells were 
removed. This pellet was then re-suspended in 2ml of PBS and processed in 
the standard way.  
 
The results showed that stained cassettes were loaded with a very high 
number of white blood cells (Fig 4.7). Amongst these, a few CK20 positive 
CTCs could be seen but with some difficulty. Results from 3 patients who 
underwent this technique are shown in Table 4.5. 
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Figure 4.7 Images taken on fluorescent microscope. A, image taken under 
UV light shows the cassette loaded with numerous cells; B, when viewed 
under green fluorescence, a CK20 positive cell is shown (circled). 
 
 
Patient 
No. 
Patient Details CTCs in 2ml 
whole blood 
CTCs in 
10ml of 
blood ficol 
1 Left hepatectomy for colon cancer with 
liver metastases 
36 0 
2 Extended right hepatectomy for 
colorectal liver metastases 
22 11 
3 Right hepatectomy for colorectal liver 
metastases 
2 4 
 
Table 4.5 The CTC counts found in patient samples when 2ml whole blood 
samples were compared with 10ml of ficolled blood.  
 
The difficulty in identifying the infrequent CTC amongst numerous white blood 
cells when processed using this technique meant inter-assessor variability 
was poor and the results did not show a significant increase in the capture of 
CTCs. These analyses were also performed on a fluorescence microscope 
rather than on confocal and therefore there was doubt as to whether the 
resolution was adequate to be certain as to whether CK20 positive cells were 
indeed CTCs.  
 
 
 
A B 
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4.2.4.2		 Processing	mononuclear	cell	 interphase	directly:	the	modified	Ficoll	
technique	
 
In later experiments the pelleting of the mononuclear interphase layer and 
washes with PBS were excluded as it was felt that centrifuging and pelleting 
might be causing “clumping” and aggregation of cells, resulting in ineffective 
filtration of white blood cells and leading to the cassettes being over loaded 
with cells.  
 
Hence the standard Ficolling technique was modified so that after the initial 
centrifugation of samples with the Ficoll density gradient solution, the 
mononuclear interphase layer was collected and directly processed in 
Parsortix using the “SEPARATION” and “STAIN” programmes.  
 
The results for 5 patients who had a 2ml whole blood sample processed in the 
standards way and a 10ml sample processed with this modified Ficoll 
technique are given in Table 4.6. The analysis of cassettes was carried out on 
confocal microscope, ensuring that only CD45- cells that stained with CK20 or 
CDX2 were counted as CTCs. Representative images of such cells are shown 
in Figure 4.8. 
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Table 4.6 Patient details and CTC counts for patients who underwent 
simultaneous processing of 2ml of whole blood alongside 10ml of whole blood 
that had undergone the modified Ficolling technique.
Patient 
No. 
Disease Staining 
reagents/ 
antibodies 
2ml 
CTC 
Number 
“Separation” 
time for 
interphase layer 
from10ml 
sample 
CTC count 
in 10ml 
interphase 
layer 
Conta-
minating 
cells 
Debris 
1 LR Sigmoid cancer 
with synchronous 
liver metastases. 
Sample taken on 
day of surgery for 
liver resection 
CK20, 
CDX2, 
CD45, TO-
PRO-3 
12 1hr 40 4 +/- + 
2 AE Recurrence of 
peritoneal and liver 
metastases after 
resection of 
primary colon 
tumour and liver 
metastases. 
CK20, 
CDX2, 
CD45, TO-
PRO-3 
21 1hr 29 56 +/- + 
3 JG Recurrent disease 
in colon with liver 
and peritoneal 
metastases. On 
palliative 
chemotherapy 
CK20, 
CDX2, 
CD45, TO-
PRO-3 
2 1hr 24 4 + +/- 
4 FS Second resection 
for liver 
metastases. 
Previous colon and 
liver resection 2 
years ago 
CK20, 
CDX2, 
CD45, TO-
PRO-3 
5 1hr 42 26 + +/- 
5 RH Metastatic 
colorectal cancer 
with liver and 
lymph nodes 
affected. Had 1 
cycle of 
chemotherapy 
CK20, 
CDX2, 
CD45, TO-
PRO-3 
8 1hr 39 24 +/- +/- 
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Figure 4.8 Images taken on confocal microscope, x400 magnification. 
Merged images of green, red and blue fluorescence showing cells that are 
positive to CK20/CDX2 (green fluorescence) and the nuclear stain TO-PRO-3 
(blue fluorescence) but not CD45 (red fluorescence).  
 
There was significantly higher numbers of cells when processed using this 
modified Ficoll technique, with 4 of the 5 patients showing an increase in the 
number of cells captured. However, only 1 patient (FS) showed a proportional 
increase in CTC number with the 5-fold increase in volume of blood. Its worth 
noting this was one of the later samples that underwent processing in this 
manner. It’s possible that increasing experience with the technique 
(particularly in the careful removal of the interphase layer without disturbing 
the red blood cell layer) might provide better results.  
 
Of all the methods trialed to increase the volume of blood that could be 
processed at one time, this method alone showed an increase in the number 
of CTCs captured with increase in volume.   
 
4.3	 Discussion	
 
The addition of CDX2 to the staining protocol made a significant improvement 
in the detection rate from metastatic colorectal cancer patients. In earlier 
experiments to optimize the staining protocol it was decided against the use of 
CDX2. This was because with the HT29 cells that were being tested, it 
seemed a high concentration of CDX2 and permeabilisation was necessary to 
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obtain positive results. Yet, this has not proven to be the case with patient 
samples. Indeed, when used at the same concentration as CK20, the 
fluorescence from CTCs is much more intense and allows easy visualization 
of these cells under confocal microscopy. It’s possible that it’s combined 
positivity to CK20 and CDX2 that causes this to occur. We have not 
performed simultaneous staining of samples with the individual antibodies to 
confirm or refute this.  
 
The ability to process larger volumes of blood using the magnetic flea would 
negate the need for a pre-processing step such as Ficoll-density gradient 
centrifugation and would be less time consuming and less labour intensive. 
The use of a magnetic stir bar has been attempted previously although in a 
different manner. Talasaz et al [123, 124] used a rotating MagSweeper bar 
coated with an antibody to EpCAM to try and capture ferrous-labelled CTCs 
from blood samples. However, here they used a vertical bar inserted into 9ml 
of whole blood diluted with PBS. They do not state the dilution factor or length 
of processing time but it’s possible that their use of a vertical stir bar caused 
less shearing forces and less cell destruction than was possible with the 
horizontally rotating bar used in this study. In the end, the use of a magnetic 
stirrer was not found to be effective when tested on patient samples during 
these experiments.  
 
The 1:1 dilution of blood with PBS to prevent clotting, whilst requiring some 
initial preparation of the sample prior to processing, would still be a fairly 
efficient method to increase the volume of blood processed. However, the 
design of the filtration system, which functions using a pressure difference 
across the filter to capture CTCs effectively, meant that changes in the 
viscosity of the solution or the velocity of flow through the machine was too 
disruptive and ultimately reduced the capture efficiency. Our understanding is 
that newer prototypes of the machine have continuous monitoring of the 
pressures within the system. It may therefore be possible to use different 
solutions with varying viscosities within the system and still obtain reasonable 
capture efficiency. In this case, such methods as diluting the blood should be 
re-tested to examine their effectiveness.  
 81 
 
It was the direct processing of the mononuclear cell interphase within the 
Parsortix machine that proved an effective technique for increasing CTC 
capture. It is worth noting that experience at collecting the interphase layer 
may play a part in the success of this technique, as it can be seen that results 
were generally better with latter patients compared to earlier ones. Yet, in only 
one patient was there a full 5-fold increase in the number of captured CTCs 
as would correlate with the increased volume from 2ml to 10ml. This may be 
due to the changes in viscosity, velocity and differential pressures as 
described above. Again, with continuous monitoring of pressures within the 
Parsortix system, it may be possible to obtain even better results. 
 
It should also be noted that the isolated mononuclear cell fraction from 10ml 
of whole blood only makes up 2-4ml of solution that undergoes processing 
and therefore, theoretically, a greater volume of whole blood could be 
processed (in multiple Ficoll-density gradient tubes if required) and the 
mononuclear cell fractions combined to be processed through Parsortix. 
However, clinical and ethical considerations should be given when obtaining 
large volumes of blood from cancer patients as they are already at risk of 
cancer induced anaemia.  
 
Although performing Ficoll density gradient centrifugation prior to processing 
increases total processing time, it is a technique commonly used in research 
and clinical laboratories and therefore should not require additional training or 
expertise. However, it does require additional materials (although the Ficoll 
solution is relatively low cost) and the availability of a centrifuge machine.  
 
For the purpose of this study the modified Ficoll density gradient 
centrifugation method was the only one found to be effective in increasing 
CTC capture when processing larger volumes of patient blood.  
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5.0	 Mutational	Analysis	of	CTCs	
 
5.1	 Introduction	
 
 
Whilst enumeration of CTCs has prognostic relevance with correlation to 
overall and progression-free survival after resection of various tumours [125, 
126], the parameters for significance, the efficiency of capture and the 
relevance of captured cells are still variably reported between studies [127]. 
The characterisation and molecular study of CTCs on the other hand, might 
prove to be more effective in personalised medicine by providing information 
for clinical surveillance in the form of stratification and monitoring of disease 
status with the hope of providing targets for effective therapies.  
 
Current advances in the treatment of metastatic colorectal cancer includes the 
use of biomarkers to predict response to targeted therapies such as epidermal 
growth factor receptor-targeted monoclonal antibodies (EGFR-mAbs) and 
tyrosine kinase inhibitors [128]. KRAS mutational status is a biomarker that is 
predictive of response to EGFR-mAbs (in particular Cituximab) therapy and 
testing for KRAS is a validated clinical practice in metastatic colorectal cancer 
therapy, recommended by the National Comprehensive Cancer Network 
(NCCN) 2012 guidelines (Version 1, 2012) [129, 130]. 
 
It is generally accepted that KRAS mutation is an early event in colorectal 
tumours and that mutational status is highly stable through the course of the 
disease [131] with a recent meta-analysis examining 986 paired primary and 
distant metastases confirming this [132]. Whilst liver metastases and primary 
tumour are almost always matched in KRAS status (96.4%) [133] there is less 
concordance with lymph node [132] or lung metastases with the latter having 
a significant level of discordance of 32.4% in one study [134]. As 
intermediaries between primary tumour and metastases, interest is now 
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growing in the examination of KRAS status in circulating tumour cells. Several 
studies have now shown that mutational analysis and detection of KRAS 
status is possible from CTCs but the technology involved in isolating the 
CTCs is both expensive and complex [127, 128, 135]. In this study, using the 
relatively low-cost and easy to use Parsortix machine, it was possible to 
obtain up to 50 CTCs from 10 ml of blood in some patients. It could therefore 
offer a practical alternative technology for isolating CTCs for mutational 
analysis to be performed.  
 
5.2		 Choice	of	mutational	analysis	technique	
 
Success at mutational analysis depends on several factors including the 
capture of sufficient number of CTCs, ability to harvest captured cells and 
minimizing contamination with non-CTC cells.  
 
PCR amplification and Sanger sequencing of the KRAS region of DNA 
extracted from CTCs was considered for this study. However, for reliable 
results the limit of detection with this technique in tissue samples was shown 
to be 30% (i.e. 30% of cells within the sample being tested have to be mutant) 
[136]. Whilst this proportion may be obtained from tumour tissue, it was 
unlikely to be obtained in Parsortix samples where contamination with white 
blood cells was too excessive. None of the previous experiments had found a 
ratio of CTCs to white blood cells that would meet this requirement. Hancer et 
al had tested the applicability of direct sequencing for the KRAS mutation in 
particular and even a 10-fold dilution of mutant CTCs within normal cells 
meant the mutation was not detected [137].  
 
It was therefore decided to use the more sensitive and specific method of 
amplifying the target gene using a real-time PCR method of cast PCR [137] 
that has been used to create protocol based kits for the detection of certain 
mutations including the KRAS mutation. In cast PCR, amplification of the 
target gene only takes place if there is a mutation, as the primers used are 
specific to each mutation and only allow amplification of that mutant allele. 
This technique has been exploited by commercial companies to design kits 
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that detect amplification by having fluorophore molecules attached to the 
primers that become activated during the amplification process. A quantitative 
PCR machine with the ability to detect and measure the fluorescence in each 
sample can then identify those samples where the fluorescence is increasing 
exponentially and therefore identify samples where there is a mutation.  
 
The KRBR™ kit by Entrogen is such a product designed to detect the 12 
commonest KRAS mutations and the V600E BRAF mutation using this 
technology. Although the manufacturers state the sensitivity for detection of a 
mutation as being 1% mutant amongst wild-type DNA, studies using the kit 
have found that as few as 0.6% mutant KRAS DNA could be detected when 
tested with artificial cancer cell lines [135]. It therefore showed more promise 
for detecting a mutation in Parsortix samples if number of captured CTCs 
could be increased using the modified Ficoll gradient centrifugation method 
for processing larger volumes of blood.  
 
5.3	 Preliminary	 experiments	 to	 ensure	 requirements	 for	 mutational	
analysis	could	be	met	
 
A series of experiments were performed to ensure that cells captured within 
the Parsortix cassettes would meet the requirements of the cast-PCR kit. It 
was necessary to demonstrate that cells obtained using the “HARVEST” 
function would provide the minimum ratio of 1% CTCs amongst white blood 
cells and also that the total number of cells obtained would provide the 
minimum quantity of DNA required (120ng) at a minimum concentration of 
1.11ng/µl to identify a KRAS mutation.  
 
5.3.1	 Measuring	ratio	of	CTCs	to	white	blood	cells	
 
Captured CTCs can be retrieved from the Parsortix cassette in a total volume 
of 210µl. However this volume will contain both the captured CTCs and white 
blood cells. The harvest volume can be collected through a ‘pulse’ system that 
delivers 21 drops measuring 10µl each. As it was necessary to maximise the 
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ratio of CTCs to white blood cells, experiments were carried out to calculate 
the number of white blood cells and CTCs in each of these drops. 
 
5.3.1.1		 Spiked	samples		
 
In the first instance, samples were processed with a known number of 
cultured PC3 cells spiked in normal volunteer blood. These samples were 
processed using Parsortix “SEPARATION” programme and the cassette 
harvested with each individual 10µl pulse collected separately, dried onto a 
microslide and stained with anti-CK20 to identify the PC3 cells and anti-CD45 
to identify the white blood cells. Each drop was then analysed to obtain the 
ratio of PC3 cells to white blood cells. The experiment was repeated on 2 
different machines. The results are given in Figure 5.3.  
 
The results showed that drops 1 to 5 contained no cells. These drops are 
most likely the volume of solution within the tubing from the cassette to the 
retrieval point. From drops 6 to 10 a few white blood cells are identified but in 
both sets of results, the CTCs only appear after drop 10, with almost all of the 
retrieved CTCs concentrated in drops 10 to 14. After this point the number of 
white blood cells remains high but without many CTCs present.  
 
 
 
 
 87 
 
 
 
Figure 5.3 Bar graphs demonstrating the ratio of white blood cells (CD45 
positive cells) to PC3 cells in individual drops from 2 different machines.  
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5.3.1.2	 Patient	samples	
 
Previous experiments with Parsortix had found the harvest of CTCs from 
patient samples to be more difficult than from spiked samples. Hence it was 
necessary to explore whether the findings above would be replicated when 
patient samples were processed in the same way. 
 
Two patients identified in whom a high number of CTCs had been found (AE - 
recurrent liver and peritoneal metastases after resection of primary; RH – 
colorectal cancer with multiple liver metastases) underwent the same method 
of processing samples and harvesting the capture in individual pulses prior to 
staining for CTCs and white blood cells. CK20 and CDX2 were used as 
antibodies to stain for CTCs whilst CD45 was used to stain for leukocytes. 
The results are illustrated in figure 5.4 and the individual counts for each cell 
population given in Table 5.4. Although previous experiments had found AE 
and RH to have a high number of CTCs (56 an 24 respectively), the number 
of CTCs in the sample harvested was not known as all of the blood obtained 
was used to capture and harvest the cells rather than to stain and enumerate. 
The “harvest efficiency” was therefore not known.  
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Figure 5.4 Bar graphs demonstrating the ratio of CTCs to white blood cells 
found in individual pulses harvested from patient samples.  
 
The results once again showed that no cells were retrieved in droplets 1 to 5, 
after which white blood cells started appearing, reaching high numbers from 
drop 9 onwards. Tumour cells were more widely distributed than with spiked 
samples, being found between drops 8 to 19 but again the higher numbers 
were within a more narrow range (drops 10 to 16).  The ratio of white blood 
cells to CTCs was also generally higher, most likely due to the lower total 
number of tumour cells within patient samples.  
 
b) Harvest of individual pulses from patient 2 
a) Harvest of individual pulses from patient 1 
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 Patient 1 Patient 2 Mean no. of 
CTCs 
Mean no. of 
PBMCs Droplet 
no. 
CTCs White blood 
cells 
CTCs White blood 
cells 
1 0 0 0 0 0 0 
2 0 0 0 0 0 0 
3 0 0 0 0 0 0 
4 0 0 0 0 0 0 
5 0 0 0 0 0 0 
6 0 10 0 0 0 5 
7 0 0 0 0 0 0 
8 1 32 0 22 0.5 27 
9 0 224 1 406 0.5 315 
10 6 274 4 238 5 256 
11 9 290 7 266 8 278 
12 3 210 1 250 2 230 
13 2 200 2 84 2 142 
14 3 294 4 206 3.5 250 
15 10 220 8 186 9 203 
16 5 96 3 100 4 98 
17 0 47 0 49 0 48 
18 0 62 0 48 0 55 
19 0 27 2 23 1 25 
20 0 25 0 15 0 20 
21 0 29 0 21 0 25 
Total 39 2040 32 1914 35.5 1977 
 
Table 5.4 Results of staining individual harvest drops for identification of 
CTCs (positive to CK20/CDX2, negative to CD45) and white blood cells 
(positive to CD45) on patient samples 
 
Due to the high contamination by white blood cells, in order to maximise the 
ratio of CTCs to white blood cells, only droplets 10 to 16 would be collected. 
The estimated number of white blood cells in these droplets would be 
approximately 1500 (as found in patient samples). To reach the 1% ratio of 
CTCs required for mutation analysis, there would need to be a minimum of 15 
CTCs in these droplets. As 92.5% of the total number of CTCs is harvested 
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within these droplets there needs to be a minimum of 16 or more CTCs 
captured and harvested.  
 
As previous experiments had captured up to 56 CTCs from a patient with 
metastatic disease, it seemed possible to obtain this number of CTCs, 
although the harvest efficiency of the Parsortix machines were not known.  
 
5.3.2	 	Determining	minimum	number	of	cells	required	for	sufficient	quantity	and	
concentration	of	DNA		
5.3.2.1		 Cells	in	PBS		
 
Before committing patient samples to extraction of DNA and trial in the 
KRBR™ kit, it was necessary to determine what minimum quantity of cells 
would provide the DNA quantity and concentration required for the use of the 
KRBR™ kit. In order to identify the KRAS mutation, 120ng of total DNA was 
required at a minimum concentration of 1.11 ng/µl.  
 
In a series of experiments, DNA was extracted from serial dilutions of HT-29 
colorectal cancer cells numbering between 10,000 to 1 cell diluted in 50µl of 
PBS. DNA extraction was performed using the Qiamp DNA extraction kit, 
following the manufacturer’s instructions. The final elution volume after DNA 
extraction was 30µl of which 25µl is received as the output. A 
spectrophotometer was used to assess the concentration and quality of DNA 
obtained.  
 
At each experiment, cell dilutions were carried out in triplicate and the mean 
concentration of 2 readings on the spectrophotometer were recorded. The 
experiment was repeated 3 times. Table 3.1 shows the DNA concentration 
per µl measured at each experiment and the calculated total quantity in 20µl 
of the eluted solution (allowing for 2 readings on the spectrophotometer and 
1µl of instrumental loss during stages).  
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No. of 
cells 
DNA concentration (ng/µl) DNA quality 
(average of 3 
experiments) 
Total DNA 
content in 
20µl 
(ng)  Exp 1 Exp 2 Exp 3 Overall average 
concentration 
260/ 
280 
260/ 
230 
10,000 0.8 4.9 7.9 4.53 1.84 1.78 90.6 
5,000 3.7 3.5 3.5 3.57 1.61 1.02 71.4 
1,000 1.7 1.5 0.6 1.27 2.07 1.63 25.4 
500 - 0.1 2.3 1.2 1.51 5.96 24 
100 1.6 1.3 2.2 1.7 1.33 4.23 34 
10 0.4 0.2 1.4 0.67 1.71 2.30 13.4 
1 - 0.0 0.6 0.3 1.19 -1.05 6 
 
Table 5.1 Results of DNA extraction when HT29 cells were spiked into sterile 
PBS  
 
The quality and purity of the DNA obtained was poor with most 260/280 
values falling short of the 1.8 value and 260/230 values suggesting there was 
significant contamination. Allowing for this, these results suggested a 
minimum of 10 cells were required to extract a consistently detectable amount 
of DNA. If all 20µl of the eluted solution could be utilized, then sufficient DNA 
would be available to carry out a few reactions in the KRBR™ kit. However, 
even with 10,000 cells there was insufficient DNA to perform all 12 reactions 
to examine for and identify a KRAS mutation as the required quantity of 120ng 
was not achieved. The lack of correlation between the number of cells entered 
and the DNA extracted also shed doubt as to the success of the DNA 
extraction technique.  
 
The minimum concentration of DNA required for a reaction was 1.11ng/µl. 
The graph below shows a line of best fit through a scatter plot of number of 
CTCs against the concentration of DNA. An estimate of the number of cells 
required to reach the required concentration of 1.11 ng/µl is calculated to be 
approximately 45 cells.  
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Figure 5.1 Scatter graph of number of cells against concentration of DNA 
obtained when using the Qiamp DNA Micro kit. The line of best fit shows that 
the number of cells required to achieve a DNA concentration of 1.11ng/µl is 
approximately 45 cells.  
 
The major limitation that could be ascribed to this experiment is that the test is 
not reflective of what would take place with actual patient samples, as the 
tumour cells were only being spiked into sterile PBS. In reality, whole blood 
samples or isolated mononuclear cell fractions containing CTCs would be 
processed through Parsortix and the harvest would contain a mix of both 
CTCs and leukocytes. Also, when captured cells are retrieved from the 
machine using the harvest function, there will be some cells that may be left 
behind in the cassette and others that may be destroyed during the retrieval 
process. Therefore the capture of a certain number of cells does not 
guarantee the retrieval of the same number for analysis.  
 
For the requirements of the KRBR™ kit, the total quantity of DNA did not need 
to arise only from CTCs but could be from a mixture of CTCs alongside white 
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blood cells (as long as the minimum ratio of 1 CTC amongst 99 white blood 
cells was achieved). Hence a second series of experiments were carried out 
to find whether CTCs spiked into whole blood samples would provide the 
required quantity of DNA.  
 
5.3.2.2		 Spiked	cells	in	whole	blood	
 
A more true-to-life and valid experiment was performed where known 
numbers of tumour cells were spiked into 10ml of whole blood and processed 
in the standard way that a patient sample would be. Therefore these samples 
had Ficoll-density gradient centrifugation performed and the mononuclear cell  
interphase layer collected and processed in Parsortix using the 
“SEPARATION” programme. The captured cells were retrieved in 200µl of 
PBS using the “HARVEST” programme and the DNA extracted using the 
Qiamp DNA Micro Kit. The volume of PBS harvested from the Parsortix 
cassette now contained a mix of CTCs and leukocytes as well as other 
contaminants captured in the cassette. The experiment was performed twice. 
The results are given in Table 5.3 
No. of cells 
spiked into 
10ml blood 
DNA extract quality Total DNA  
in 20 µl 
(ng) 
 Ng/µl 260/280 260/230  
Experiment 1 
10 0.7 2.38 0.05  14 
50 1.2 -1.2 0.06  24 
100 1.0 0.95 0.09  20 
1000 2.3 3.06 0.15  46 
Experiment 2 
10 0.6 -1.13 0.06 12 
50 1.1 -8.99 0.07 22 
100 1.6 3.00 0.11 32 
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Table 5.3 Results of DNA extraction when HT29 cells were spiked into 10ml 
of whole blood. 
 
The minimum number of cells required to obtain 10ng was again 10 CTCs 
spiked into a 10ml sample and once again the 120ng of DNA that would be 
required to test for all 12 KRAS mutations was not obtained. The minimum 
number of cells required to obtain the concentration of 1.11ng/µl, however, 
was found to be less than previously, at approximately 36 cells. 
 
 
 
Figure 5.2 Concentration of DNA obtained when CTCs were spiked into 
whole blood samples and the harvest from Parsortix underwent DNA 
extraction using the Qiamp DNA Micro Kit.  
 
The quality of DNA obtained in these experiments were again a major 
concern as the 260/280 values were far from 1.8 (which would indicate a 
“pure” sample) and the majority of readings were much worse than from 
experiments where cells were diluted in PBS. This indicated that there was a 
1000 4,3 1.09 1.65 86 
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significant amount of contamination and the DNA obtained was of very poor 
quality.  
 
5.3.3	 Conclusions	from	preliminary	experiments	
 
Despite repeated attempts at processing whole blood samples spiked with 
HT29 cells, the quantity of DNA extracted even with high numbers of CTCs, 
such as 100 or 1000 (which was much higher than we were able to harvest 
from our patient population) was inconsistent and of poor quality. This was 
either due to lack of experience by the user, inability of the kit to process the 
small number of cells we were isolating or because during retrieval from the 
Parsortix machine, the cells were being damaged or destroyed making 
subsequent DNA extraction unsuccessful.  
 
The conclusion from these series of experiments was that although the 
minimum ratio of CTCs amongst white blood cells could be achieved in some 
patients, the quantity and quality of DNA extracted from the harvest solution 
would not be sufficient to obtain successful results from the KRBR™ kit.  
 
5.4	 Whole	Genome	Amplification	(WGA)	
 
Whole genome amplification (WGA) has been successfully proven to work as 
an intermediary step to mutational analysis on CTCs in recent studies. A 
literature search identified 2 amplification kits that have been successful in 
extracting DNA from small volumes of CTCs. These were the Repli-G kit by 
Qiagen [138] and the Ampli1™ kit by Silicon Biosystems [127] of which the 
Ampli1™ kit was purchased to trial in this study.  
 
A full description of the Ampli1™ WGA kit’s function is given in the materials 
and methods chapter. In brief, the harvest solution containing the CTCs are 
collected in a 200 µl micro-centrifuge tube which is centrifuged to pellet the 
cells at the base. The supernatant fluid is removed, adding only 1µl of 0.2% 
PFA to preserve the cell pellet. This pellet was often not visible to the naked 
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eye and therefore presumed to be at the base following centrifugation. The 
method of centrifugation to ensure all of the cells within the solution are 
collected at the base of the micro tube and the choice of solution in which to 
preserve the pellet along with limitations of the method were discussed with 
the manufacturer of the kit at Silicon Biosystems, Bologna, Italy.  
 
Whilst it was possible to amplify extracted DNA, the manufacturers felt that if 
cells were preserved intact, the amplification is much more likely to succeed 
and provide higher quality DNA. Therefore, the harvested cell pellet in its 
intact form was stored in 0.2% PFA prior to use.  
 
The thermo-cycler programme for each step in the process was programmed 
into the thermo-cycler exactly according to manufacturer’s instructions.  
 
5.5	 Analysis	of	amplified	DNA	from	HT-29	cells	for	BRAF	mutation	
 
For spiked experiments 10ml whole blood samples from normal volunteers 
were spiked with a varying number (10, 100 or 500) of HT-29 cells diluted into 
the samples. These underwent Ficoll-density gradient centrifugation to obtain 
the mononuclear interphase layer which was harvested and directly 
processed in Parsortix. The captured CTCs were then harvested and 
collected as pulse droplets. This solution was centrifuged, the supernatant 
removed and the cell pellet stored 0.2% PFA in -200C until use as instructed 
by the manufacturer. The experiment was then repeated in precisely the same 
way for another set of spiked blood samples. 
 
A negative control was performed where 10µl of sterile PBS was diluted into a 
10ml whole blood sample from a normal volunteer and processed in the same 
way as above with the harvested pellet stored as described. A positive control 
was carried out where a visible pellet consisting of >500,000 HT29 cells was 
inserted into a normal volunteer whole blood sample and processed, 
harvested and stored in the same way.  
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The stored pellets from the 8 spiked samples were processed at the same 
time using the Ampli1™ kit. Because of the minute volumes of reagents that 
need to be distributed to each specimen it was recommended by the 
manufacturers that reagent mixes are created for 10 reactions at a time and 
multiple samples are analysed in the same run.  
 
The end product of the whole genome amplification reactions were subject to 
spectrophotometer analysis and the measurements are given in Table 5.7.  
 
Spiked sample ng/µl 260/280 260/230 
10 908.0 1.96 1.54 
10 (2) 889.9 1.98 1.69 
100 876.4 1.96 1.59 
100(2) 902.8 1.95 1.53 
500 918.3 1.94 1.49 
500 (2) 913.2 1.93 1.51 
-ve control 1002.5 1.99 1.77 
+ve control 955.6 1.90 1.47 
 
Table 5.7 Results of spectrophotometer analysis of WGA products from 
samples obtained from spiking HT29 cells into volunteer whole blood.  
 
 
The DNA obtained from amplification of intact cells was of much better quality 
than DNA extracted directly from harvested cells as indicated by the 260/280 
values which were more consistent and closer to 1.8. The quantity of DNA 
was more than enough to meet the requirement of the KRBR™ kit for 
identifying KRAS mutations.  
 
Following discussion with the manufacturers, it was also felt it would be 
prudent to check that the DNA was the product of intact cells within the 
sample having been amplified, rather than contaminating free DNA. Hence 
the “QC-Kit” was purchased and used to analyse the samples prior to 
performing mutational analysis. This kit carries out a multiplex PCR of four 
genes (markers) to check the quality of the Ampli1™ -WGA product. If all four 
markers are found to have amplified, it is a good indication that the DNA was 
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the product of one or more intact cells within the sample having been 
amplified. 
 
The above samples were subjected to QC Kit analysis and the results from 
agarose gel electrophoresis are shown in Figure 5.5. 
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Figure 5.5 Results of agarose gel electrophoresis to assess the quality of 
WGA products of spiked HT29 cell samples.  
 
1 2 3 4 5 6 7 8 9 10 11  
 
 
Lane Number Content Confirmation of whole cell 
amplification 
1 Ladder - 
2 WGA product from 10 (1) HT29 cels Yes 
3 WGA product from 10 (2) HT29 cels Yes 
4 WGA product from 100 (1) HT29 cels Yes 
5 WGA product from 100 (2) HT29 cels Yes 
6 WGA product from 500 (1) HT29 cels Yes 
7 WGA product from 500 (2) HT29 cels Yes 
8 WGA product from negative control 
(PBS only inserted into whole blood) 
No 
9 WGA product from positive control 
(HT29 cell pellet dissolved in whole 
blood) 
Yes 
10 QC kit internal negative control No 
11 QC kit internal positive control Yes 
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Lanes 2 to 7 (samples that contained spiked HT29 cells) showed good quality 
amplification products as all 4 markers were found to have amplified during 
PCR (NB. The second marker maps onto a polymorphic region with the 
amplicon length of 108-166 bp and therefore can be heterozygous showing 
one or two bands as seen here, accounting for the blurriness in this region). 
Both positive controls from the spiked sample and the QC kit’s internal control 
(lanes 9 and 11) also showed amplification of DNA from intact cells whilst the 
negative controls (lanes 8 and 10) showed negative results. The control 
results were, therefore, as expected.  
 
With the ample DNA now available, mutational analysis was performed on all 
8 samples for the BRAF mutation using Entrogen’s cast PCR kit. This BRAF 
mutation is known to be present in the HT29 cell line and only 10ng of DNA 
was required to test for the single reaction in the KRBR™ kit which would 
indicate this mutation. 
 
The amplification product had to first be diluted down to a suitable 
concentration so that the KRBR™ reactions would not be overloaded by DNA. 
The diluted concentrations and quality of DNA were confirmed with 
spectrophotometry.  
 
The KRBR™ reactions were tested with the appropriate primers to test for the 
BRAF mutation. As explained in the Materials and Methods chapter, the 
analysis of the results depends on the Ct value obtained for the HEX and 
FAM values. The HEX Ct value must be between 25 and 30 for further 
analysis of the FAM fluorescence. When the HEX Ct value is in this range, 
then the presence of a mutation is indicated by a FAM Ct value below 38.5.  
 
The results from analysis of samples spiked with HT29 cells are given in 
Table 5.8 and show that the BRAF mutation was detected in all but one of the 
samples that contained 10 CTCs, confirming that whole genome amplification 
worked effectively to amplify DNA from harvested CTCs to provide DNA of 
sufficient quantity and quality for mutational analysis and that the lower limit of 
detection with this assay may be 10 CTCs in 10ml of whole blood. 
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Table 5.8 Results of the KRBR™ kit cast PCR analysis to examine for BRAF 
V600E mutation amongst WGA samples of HT29 spiked blood samples.  
 
One discrepancy in the results was the positive control sample, which was 
spiked with a pellet of HT29 cells, did not indicate the presence of a mutation 
despite the product of amplification having been demonstrated to be from 
intact cells. The reason for this is unclear.  
 
CTCs in sample Ct value for 
HEX fluoresence 
Ct value for 
FAM fluoresence 
RESULT 
10 28.87 No Ct Negative 
10 (2) 28.5 36.09 Positive 
100 29.66 31.72 Positive 
100 (2) 29.53 31.34 Positive 
500 28.85 30.58 Positive 
500 (2) 29.82 32.97 Positive 
Negative control 
from WGA (PBS 
only dissolved in 
whole blood) 
No Ct No Ct Negative 
Positive control 
from WGA 
(HT29 cell pellet 
dissolved in 
whole blood) 
31.52 31.05 Negative 
KRBR™ kit’s 
internal negative 
control 
No Ct No Ct Negative 
KRBR™ kit’s 
internal positive 
control 
29.54 29.54 Positive 
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5.6	 Analysis	of	amplified	DNA	from	A549	cells	KRAS	mutation	
 
Having shown that the BRAF mutation could be detected in HT29 cells spiked 
into whole blood samples, a similar spiked experiment was performed to 
confirm whether the KRAS mutation could be detected from cells known to 
contain this mutation. For this purpose the A549 cell line was used which is 
known to have the KRAS mutation G12S.  
 
Varying numbers of A549 cells (5, 10, 50 and 100) were spiked into 10ml 
samples of normal volunteer blood and processed through Parsortix. The 
experiment was repeated a second time as before with all the stored harvest 
specimens having undergone WGA at the same time.  
 
A negative control that underwent WGA was again carried out where only 
PBS was inserted into the volunteer blood sample. A positive control that 
underwent WGA was performed where an excess of 500,000 cells were 
inserted into a whole blood sample. The spectrophotometer analyses of 
amplification products are shown in Table 5.9. 
 
Harvest ng/µl 260/280 230/280 
Experiment 1 
5 1242.9 1.90 1.64 
10 1233.6 1.92 1.87 
50 1234.0 1.92 1.75 
100 1160.5 1.92 1.76 
Experiment 2 
5 1398.8 1.76 1.11 
10 1171.2 1.93 1.79 
50 1206.4 1.92 1.80 
100 1199.5 1.92 1.77 
    
-ve 1325.1 1.95 1.89 
+ve 1257.1 1.94 1.81 
 
Table 5.9 Results of spectrophotometer analysis of WGA products from 
samples obtained by spiking A549 cells into whole blood.   
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Once again, high quality DNA was obtained which was checked using the QC 
kit to ensure that amplification had been the product of intact cells within the 
samples. The results, as visualised on gel electrophoresis are shown in 
Figure 5.6. 
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Figure 5.6 Results of agarose gel electrophoresis to assess whether whole 
cell amplification had taken place when WGA was performed on A549 spiked 
samples.   
 
1 2 3 4 5 6 7 8 9 10 11 12 13 
 
 
Lane Number Content Confirmation of whole cell 
amplification 
1 Ladder - 
2 WGA product from 5 A549 cells No 
3 WGA product from 5 A549 cells Yes 
4 WGA product from 10 A549 cells Yes 
5 WGA product from 10 A549 cells Yes 
6 WGA product from 50 A549 cells Yes 
7 WGA product from 50 A549 cells Yes 
8 WGA product from 100 A549 cells Yes 
9 WGA product from 100 A549 cells Yes 
10 WGA product from negative control (ie. 
0 A549 cells) 
No 
11 WGA product from positive control (ie 
>500,00 A549 cells) 
No 
12 QC kit internal –ve control No 
13 QC kit internal +ve control Yes 
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The results showed that the majority of spiked samples from both experiments 
produced amplified DNA from intact cells. The negative control that underwent 
WGA suggested that some DNA had been amplified but not from intact cells. 
This may be an indication that there was some contamination with DNA 
fragments. The control samples from the QC kit also produced appropriate 
results but the positive control sample that underwent WGA (>500,000 A549 
cells processed in a whole blood sample) only showed amplification for 1 of 
the 4 markers, the reason for which is unclear.  
 
All the samples that underwent WGA amplification were tested for the A549 
cells’ KRAS mutation. As before, samples were diluted down to reach a DNA 
concentration approximating 10ng/µl before being tested in Entrogen’s cast 
PCR kit. Unlike the BRAF mutation, for which there is only one variation, the 
KRAS mutation has several different mutations of which 12 could be tested for 
by the KRBR™ kit. Due to limitations on the amount of reagents remaining in 
the kit (which has a high purchase cost) it was felt that testing for all 12 
mutations would be inefficient and unnecessary when it was known which 
mutation was under examination. However, it was also necessary to 
demonstrate that false positive results were not being obtained and therefore 
the 7 commonest mutations were examined in these samples.  
 
The results are given in Table 5.10 and show Ct values for both HEX and 
FAM fluorescence found in each sample. Those reactions where the HEX and 
FAM values confirmed the presence of a mutation are highlighted in green.  
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Table 5.10 Ct values obtained when harvested cells underwent WGA prior to 
testing with the KRBR™ kit. When Ct values of HEX and FAM fluorescence in 
indicate the presence of a mutation, that reaction is highlighted in green.  
 
In one of the 2 samples that contained 10 cells and for all other samples with 
higher number of cells, the appropriate (G12S) mutation was detected. It was 
not detected in either of the samples containing 5 cells.  Once again the limit 
of detection appears to be 10 cells per 10ml of whole blood.  
 
In some of these samples the G12V or G12D mutations were also found to be 
positive. The manufacturers of the KRBR™ kit state “Due to cross-reactivity, 
some samples may have positive signals for multiple mutations. In such 
cases, the sample is positive only for the mutation that corresponds to the 
reaction with the most prominent signal (lowest Ct value)”. In all cases with 
KRAS 
Mutation 
 Number of A549 cells spiked into 10ml whole blood 
  5 5  10 10  50 50  100 100  0 (-VE 
control) 
>500,000 
(+VE 
control) 
G12R Hex No Ct No Ct 26.97 26.71 27.26 26.99 28.55 28.22 No Ct No Ct 
FAM No Ct No Ct No Ct No Ct No Ct No Ct No Ct No 
Ct 
No Ct No Ct 
G12C Hex No Ct No Ct 27.11 26.76 27.11 27.12 27.96 No 
Ct 
No Ct No Ct 
FAM No Ct No Ct No Ct No Ct No Ct No Ct No Ct No 
Ct 
No Ct No Ct 
G12S Hex No Ct 27.27 26.93 26.59 27.36 27.41 27.94 27.84 No Ct No Ct 
FAM No Ct No Ct 34.12 No Ct 35.11 33.94 32.64 32.79 No Ct No Ct 
G12V Hex No Ct 27.72 27.54 27.79 No Ct 27.05 27.57 27.79 No Ct No Ct 
FAM No Ct No Ct 35.99 No Ct No Ct 35.03 33.66 34.96 No Ct No Ct 
G12A Hex No Ct 27.09 25.8 26.34 26.88 26.89 27.44 27.83 No Ct No Ct 
FAM No Ct No Ct No Ct No Ct No Ct No Ct No Ct No 
Ct 
No Ct No Ct 
G12D Hex No Ct 27.48 26.93 27.23 27.07 27.62 27.95 No 
Ct 
No Ct No Ct 
FAM No Ct No Ct 37.22 No Ct 36.78 37.24 No Ct No 
Ct 
No Ct No Ct 
G13D Hex No Ct 27.5 27.34 No Ct 27.15 27.43 27.98 28.73 No Ct No Ct 
FAM No Ct No Ct No Ct No Ct No Ct No Ct No Ct No 
Ct 
No Ct No Ct 
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the spiked samples, the G12S mutation did have the lowest Ct value and 
hence these results are taken as appropriate. 
 
5.7	 Mutational	analysis	of	patient	samples	
 
To test whether harvesting CTCs to undergo WGA and mutational analysis 
would work on patient samples, patients with a known KRAS status were 
recruited.  
 
Patients with metastatic colorectal cancer were recruited from Oncology 
clinics for participation in this stage of the study. In particular, patients who 
had previously had a tumour resected and KRAS test performed by 
conventional methods (ie. on tumour tissue samples by the hospital pathology 
department) were targeted so that results could be correlated with those of 
the hospital. Because chemotherapy has been shown to reduce CTCs, the 
subgroup of patients not currently undergoing chemotherapy were particularly 
targeted, although the rarity of these patients attending the hospital, meant 
this was not always possible.  
 
Thus the criteria for recruitment were: 
 
Primarily, 
1) Known metastatic disease of colorectal origin 
2) Disease currently present in 2 or more organs 
 
Secondarily,  
3) Previously had colorectal tumour resected with KRAS test result 
available 
4) Not currently on chemotherapy (either not suitable due to co-
morbidities, likely to need chemotherapy but not yet commenced or 
finished the last cycle more than 6 weeks ago) 
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After obtaining consent, recruited patients had 2ml of blood drawn from a 
peripheral vein or from a Picc line (already in-situ for chemotherapy 
administration) into EDTA containing tubes. These were transferred to the 
laboratories at the University of Surrey within 2 hours and placed on a ‘rocker’ 
to keep the sample mobile until processing was performed on the same day. 
Two milliliters of whole blood was processed using the “SEPARATION” and 
“STAIN” programmes to enumerate the number of CTCs. Those patients who 
were found to have more than 5 CTCs in 2 ml of whole blood were asked to 
return to have a further 30ml drawn for mutational analysis (if they were not 
clinically or haematologically anaemic). 
 
From 20 patients who met the recruitment criteria and underwent testing with 
2ml of whole blood, 6 patients were found to have more than 5 CTCs and 
were called back to undergo mutational analysis.  
 
From these patients, 30ml of whole blood was drawn from a peripheral vein 
and Ficoll density-gradient centrifugation performed within 2 hours of 
collection. The mononuclear cell interphase was collected in an empty 10ml 
EDTA vacutainer and the sample processed with Parsortix using the 
“SEPARATION” programme. Once completed, the harvest was collected 
using “PULSE HARVEST” programme with droplets 8 and onwards collected 
in a 200µl microcentrifuge tube. This tube was centrifuged at 300 rcf for 10 
minutes before removing the initial supernatant and then centrifuged a second 
time at 300 rcf for 15 minutes before carefully removing the remaining 
supernatant whilst leaving behind a tiny cell pellet invisible to the naked eye. 
One microlitre of 2% PFA was placed on top of this pellet, centrifuged to 
collect all of it at the base and then stored at -200C prior to use. All samples 
were processed and stored on the same day. All six patients were recruited 
within 6 weeks and therefore the longest time a sample was stored at -200C 
was 6 weeks.  
 
All 6 of these samples underwent whole genome amplification alongside a 
negative control (1µl of sterile PBS containing no cells) and a positive control 
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(1µl of PBS containing approximately 10,000 A549 cells). The products were 
measured on a spectrophotometer and the results shown below: 
 
Name WGA DNA ng/µl 260/280 260/230 
BS 1068.0 1.95 1.67 
BD 1215.1 2.00 1.72 
JO 1245.2 1.85 1.21 
JH 1101.3 1.96 1.73 
RL 1068.5 1.97 1.58 
RH 936.2 1.94 1.47 
-ve 1199.6 1.94 1.55 
+ve 1135.8 1.97 1.73 
 
Table 5.11 Spectrophotometer analysis of WGA products from harvested 
specimens 
 
The amplification products also underwent testing with the QC kit to check 
whether the whole cell genome had been amplified. The results of gel 
electrophoresis are shown in Figure 5.7.  
 
Patient BD did not have intact cells that underwent DNA amplification but 
patients BS, JO, JH, RL and RH did. Unfortunately the control samples that 
underwent WGA produced confusing results. The negative control (lane 8) 
showed amplification of several fragments of DNA but not those being 
examined for, indicating a negative result for the presence of intact cells 
(which was appropriate). The positive control of A549 cells spiked into PBS 
(lane 9) did not produce any definitive bands, again indicating that intact cells 
were not present or that correct amplification did not occur (which was not 
expected). As found with previous experiments with the Ampli1™ kit, it seems 
that inserting a high number of CTCs in whole blood for use as positive 
control does not result in successful amplification of DNA from the harvested 
cells.  
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Figure 5.7 Results of agarose gel electrophoresis to assess the quality of 
WGA products from patient samples.  
 
1 2 3 4 5 6 7 8 9 10 11 12 
 
 
Lane Number Content Confirmation of whole cell 
amplification 
1 Ladder - 
2 WGA product from patient BD No 
3 WGA product from patient BS Yes 
4 WGA product from patient JO Yes 
5 WGA product from patient JH Yes 
6 WGA product from patient RH Yes 
7 WGA product from patient RL Yes 
8 WGA product from Negative control 
(PBS dissolved in whole blood) 
No 
9 WGA product from Positive control 
(A549 cell pellet dissolved in whole 
blood) 
No 
10 QC kit internal –ve control No 
11 QC kit internal +ve control Yes 
 
 
 
 
 
 112 
All 6 patients’ amplified DNA was tested for KRAS mutations using Entrogen’s 
KRBR™ kit according to the manufacturer’s instructions.  
 
In the case of BS, JO, JH and RH, on the first run the results showed that 
insufficient DNA had been inserted into each reaction (as shown by a HEX Ct 
value of greater than 30) and therefore a second run was performed with 1.5 
times the previous amount of DNA (approximating 30ng instead of 20ng per 
reaction). On this occasion, the results for RH again suggested that 
insufficient DNA had been inserted but due to lack of sufficient primers that 
came with the KRBR™ kit, the experiment was not repeated for this patient.  
 
The DNA from patient BD did not undergo mutational analysis as the QC kit 
indicated that DNA was not from intact cells. 
 
A positive control was included, which was an internal control provided with 
the KRBR™ kit and was run on 3 of the possible mutations. A negative control 
was included, which was PBS only inserted into each reaction.  
 
The results shown in Table 5.12 again show the Ct values for HEX and FAM 
fluorescence in each reaction. Those reactions in which the Ct values suggest 
the presence of a mutation are highlighted in green. Only one mutation was 
detected and this was for patient JH. The mutation was G13D.  
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Table 5.12 Ct values obtained when harvest from patients with high CTC 
counts underwent WGA and then testing with the KRBR™ kit. For each 
sample, shown in columns, the Ct values of the HEX and FAM fluorescence 
are given. Those samples where the Ct values suggested the presence of a 
KRAS mutation are highlighted in green.  
 
 
  
    Patients known to be  
KRAS mutant 
Patients known to 
be KRAS wild-
type 
KRAS 
Mutation 
 +ve 
control 
- ve 
control 
JH RH BS RL J0 
G12R Hex  No Ct 29.33 30.89 27.64 29.87 28.53 
FAM  No Ct No Ct No Ct No Ct No Ct No Ct 
G12C Hex  No Ct 28.92 31.21 27.42 29.99 28.37 
FAM  No Ct No Ct No Ct No Ct No Ct No Ct 
G12S Hex  No Ct 29.08 30.95 27.55 29.82 28.14 
FAM  No Ct 39.09 No Ct No Ct No Ct No Ct 
G12V Hex  No Ct 29.06 31.31 27.39 29.74 28.46 
FAM  No Ct 38.21 39.56 No Ct No Ct No Ct 
G12A Hex  No Ct 29.11 30.85 27.54 29.65 No Ct 
FAM  No Ct No Ct No Ct No Ct No Ct No Ct 
G12D Hex  No Ct No Ct 31.04 27.55 29.85 28.39 
FAM  No Ct No Ct No Ct 38.51 No Ct No Ct 
G13D Hex  No Ct 29.08 31.95 27.54 29.8 28.32 
FAM  No Ct 35.96 39.43 38.8 No Ct No Ct 
Q61R Hex 28.49 No Ct 28.96 30.97 No Ct 29.8 28.17 
FAM 28.8 No Ct No Ct No Ct No Ct No Ct No Ct 
Q61H Hex 28.22 No Ct No Ct 30.68 27.69 29.56 18.31 
FAM 27.65 No Ct No Ct No Ct 38.72 39.42 No Ct 
Q61L Hex 27.86 No Ct 28.87 30.73 27.25 29.41 No Ct 
FAM 28.05 No Ct No Ct No Ct No Ct No Ct No Ct 
K117X Hex  No Ct 28.92 28.15 27.17 29.86 30.77 
FAM  No Ct No Ct No Ct No Ct No Ct No Ct 
A146X Hex  No Ct 34.17 No Ct 33.77 31.25 33.9 
FAM  No Ct No Ct No Ct No Ct No Ct No Ct 
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Table 5.13 shows the patients’ KRAS status as determined by the hospital 
pathology lab testing on resected tumour tissue samples and the 
corresponding result obtained from mutational analysis of their CTCs.  
 
Patient KRAS status of 
tumour tissue 
KRAS status of 
isolated CTCs 
Concordance? 
JH Mutant (Codon 13) Mutant – G13D Yes 
RH Mutant Insufficient DNA - 
BS Mutant (G12C) Wild-type No 
RL Wild-type Wild-type Yes 
JO Wild-type Wild-type Yes 
 
Table 5.13 KRAS status of patients as reported from tissue samples obtained 
during previous resections compared to KRAS status detected from CTCs. 
 
The mutation detected from the CTCs of patient JH was concordant with the 
mutation detected from previous tissue analysis. Although the hospital records 
did not bear the exact mutation, they were able to state that it was in codon 
13. As the G13D mutation is the only mutation in codon 13 examined for by 
the KRBR™ kit, the result appears to be accurate.  
 
As mentioned above patient RH did not have sufficient DNA to form valid 
results and due to insufficient primers it was not possible to perform the test 
again with increased DNA.  
 
No mutation was detected in the CTCs from patient BS who was found to 
have a mutation in tumour tissue (G12C). In the reaction corresponding to this 
particular mutation, the Ct value for FAM fluorescence was “No Ct” despite 
the HEX fluorescence indicating that sufficient DNA was present. This 
indicates either that the G12C mutation was not present in the CTCs or the kit 
failed to successfully identify a mutation that was present.  
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Both patients RL and JO were known to be wild type and appropriately, they 
did not contain a KRAS mutation when tested with the KRBR™ kit. Therefore 
these results were concordant.  
 
 
5.8	 Discussion	
 
The results suggest that it is possible to isolate CTCs from patient samples 
using Parsortix and detect a KRAS mutation but amplification of DNA is 
necessary as an intermediary step. The quantity, quality and purity of DNA 
obtained from directly extracting DNA from harvested cells was simply 
insufficient to perform successful mutational analysis. It may be that the low 
number of cells harvested from Parsortix cassettes makes conventional DNA 
extraction methods unsuitable for downstream analysis.   
 
Other groups have noted problematic issues with Entrogen’s kit when using 
unamplified DNA. When Mostert et al [135] tested the KRBR™ kit on 9 
patients known to have KRAS mutation in tissue samples with CTCs ranging 
in number 0-37, captured using CellSearch, the KRBR™ kit did not detect a 
mutation in any of them.  
 
However, as the amount of DNA obtained from individual cells is reported to 
be in the order of picograms, it seems reasonable, as other similar studies 
have also found, that it is necessary to perform an amplification step prior to 
mutational analysis. It may be that with increasingly more sensitive technology 
becoming available, for example next generation sequencing, amplification of 
DNA may become unnecessary.  
 
A possible explanation for why there was a discrepancy between one of the 
patients found to have a mutation on the primary tumour and yet no mutation 
on CTC analysis despite sufficient DNA being available, may be that in a 
minority of cases (5-20%) the KRAS status may vary between the primary and 
secondary tumours [139, 140]. Indeed it has been suggested that the 
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acquisition of such mutations may be a part and parcel of the continuous 
mutations that take place in order for cells from the primary tumour to become 
metastatic and that even a mutation in the KRAS gene itself might contribute 
to the metastatic potential of cells [128].  It seems unlikely that a primary 
tumour, which already harbours a KRAS mutation, would produce CTCs that 
are wild-type. Yet, Fabbri et al [127] found this to be the case when he 
examined the KRAS status of 26 primary tumours and CTCs isolated from the 
same patients. In 7 of the 12 patients who had a KRAS mutation in the 
primary tumour, there were CTCs that were found to be wild-type. It’s also 
possible that heterogeneity within the primary tumour means some cells are 
KRAS mutant whilst others are not and that wild-type CTCs may arise from 
wild-type tumor cells even in a patient known to have KRAS mutation. Indeed, 
in one patient in their study there were CTCs with 3 different KRAS mutations. 
The features of intra-tumoural heterogeneity in studies and the problems this 
poses is becoming a common feature of literature examining mutational status 
of primary and secondary tumours [141-146]. 
 
It should be noted that with the patients in this current study, CTCs were often 
isolated a year or more after the primary tumour was resected (and on which 
the initial KRAS testing was performed). Therefore the captured CTCs may be 
derived from metastases that existed since the time of resection (although 
undetected) or they may be from new tumours that have arisen since. Other 
potential explanations for the lack of detection of a mutation from CTCs when 
one was present in the primary tumour (as in the case of patient BS) may be 
that normal epithelial cells or leukocytes were captured and amplified in the 
harvest. The lack of a negative depletion of white blood cells during the 
processing, allowing contaminants to be present in the harvest, may be a 
weakness of this study. Further experiments addressing these issues are 
needed to confirm or discard this hypothesis.  
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6.0	Discussion	
 
In the UK approximately 46,000 new cases of colorectal cancer are diagnosed 
every year, making it the third commonest cancer in men and women. Whilst 
surgical resection still remains the only hope of cure 45% of these patients will 
still develop distant metastases after surgery [1]. This phenomenon is largely 
attributed to the dissemination of tumour cells from the primary tumour site 
before or during surgery. The identification of tumour cells in the blood of 
patients either intraoperatively or post surgery has correlated with tumour 
recurrence as well as decreased disease-free and overall survival [80] [83]. 
Furthermore, the presence of CTCs in peripheral blood has been shown to be 
an independent predictor of prognosis in several cancers including colorectal 
[74]. Capture of CTCs may not only be of prognostic value and inform us of 
the effectiveness of therapy [44, 45, 79] but their further study and analysis 
may also educate us of their origin from primary or metastastic tissue [47], 
shed light on their evolution during treatments to develop drug resistance [88, 
147] and guide our choice of therapy [44].  
 
In colorectal cancer, several studies have shown that tumours harbouring the 
KRAS mutation are much less likely to respond to anti-EGFR therapy [90, 91]. 
The KRAS mutation status has therefore become a predictive biomarker that 
has been clinically validated for use in metastatic colorectal cancer (mCRC) 
and is recommended in the NCCN 2012 guidelines [129, 130].  Whilst it is 
accepted that occurrence of KRAS mutation is an early event which is stable 
through the course of the disease [132], studies are beginning to show there 
is discordance between the KRAS status of primary tissues and isolated 
CTCs [127]. The ability to monitor KRAS status by performing mutational 
analysis on CTCs, even when the status of the primary is known, may have 
clinical relevance for therapy.  
 
Furthermore, not all mCRC patients with wild-type KRAS are responders [128] 
and this may be due to mutations in other genes such as BRAF, PIK3CA and 
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PTEN [148, 149] and even due to the discordance in KRAS mutational status 
between the primary tumour and metastatic lesions [89, 150, 151]. The study 
of KRAS mutational status between primary tumour, its metastases and their 
intermediary CTCs may shed light on the reason why some patients with 
KRAS wild-type tumours still appear to be resistant to anti-EGFR therapy and 
pave the way for more effective colorectal cancer treatment.   
 
The premise of this study was to capture and isolate CTCs using a 
combination of immunohistochemical and size-based filtration techniques with 
the aim of performing mutational analysis. Central to the study was the uses 
of a novel cell capture and harvest technology named Parsortix.  
 
Our initial experiments checked the feasibility of using Parsortix to capture 
CTCs from patient samples. We targeted the clinically relevant cytokeratin-20 
antigen as the marker for colorectal tumour cells as it was reportedly 
expressed by 85-90% of colorectal primary and secondary tumours with 
specificity over 95% [152-154]. Although we found CK20 positive cells present 
in a majority of 2ml samples taken from the peripheral or hepatic vein of 
patients undergoing surgery (detection rate 65% and 72% respectively), with 
confocal analysis it was found that almost all CK20 positive cells were also 
positive to CD45 and were not CTCs but, most likely, granulocytes with a 
stable background expression of CK20 [117]. Indeed in the few instances 
where CK20+CD45– cells were found, these were much larger (30-50 µm in 
diameter) than the CK20+CD45+ cells (10-20µm in diameter). This highlights 
the importance of accounting for background stable expression of cytokeratins 
by some white blood cells (in particular granulocytes) and the deficiency in 
using cytokeratins for detection of CTCs.  
 
It may have been that incidence of granulocyte contamination would be 
reduced if samples had undergone prior density-gradient centrifugation and 
only the monocyte layer had been collected with care taken not to disturb the 
adjacent granulocyte layer. However, even later in the study when the 
mononuclear cell fraction was harvested from the blood of patients with 
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metastatic cancer, even though care was taken not to visibly disturb the 
granulocyte layer CK20+CD45+ granulocytes were still noted during analysis.  
 
Despite the rarity of CK20+CD45- CTCs in the blood of patients undergoing 
surgery, it was possible to confirm that Parsortix was able to capture 
immunohistochemically proven CTCs in patient samples. A greater frequency 
and volume of CK20+CD45- CTCs were identified in the blood of patients with 
metastatic colorectal cancer. Experiments were undertaken to increase the 
number of cells that could be captured in order to perform further analysis and 
this was achieved with the addition of CDX2 to the staining protocol (which 
increased the detection rate from 50% to 90%) and performing Ficoll-density 
gradient centrifugation to seperate and process the mononuclear cell fraction 
directly through Parsortix, which effectively increased the volume of blood that 
could be processed and therefore increased the yield of CTCs.  
 
Although it would be desirable to minimise the number of stages in obtaining 
an enriched CTC population, the Ficoll density gradient centrifugation seems 
a necessary intermediary step. Recent advances in the prototypes of 
Parsortix machines may make other simpler techniques valid but with the 
machines available for this study and the widespread awareness of the 
technique of Ficolling it seems a reasonable compromise. One alternative 
which we were not able to test during this study may have been the use of the 
Oncoquick technology to perform the initial density gradient centrifugation 
which has been shown to reduce the loss of CTCs into adjacent layers and 
increase depletion of mononuclear cells [40].  
 
When droplets harvested using the “PULSE HARVEST” programme were 
analysed, there were considerably fewer white blood cells than with the other 
tested methods of CTC enrichment, yet the average number of white blood 
cells were found to be almost 2000. Whilst we were able to obtain the 1% 
purity of CTCs amongst white blood cells needed for cast PCR to be effective 
in some patients, for progress towards developing the technology for clinical 
use where considerably fewer CTCs may need to be analysed, this 
contamination needs to be reduced further. Similar CTC capture technologies 
 121 
report a white blood cell contamination level of approximately 1000 leukocytes 
after CTC enrichment [135, 155].  
 
The addition of an amplification stage seems an unavoidable component for 
mutational analysis, as most methods of detecting mutation require a 
minimum quantity and quality of DNA that cannot be obtained by directly 
extracting DNA from isolated cells. The patients for whom mutational analysis 
is going to be clinically relevant in determining therapy are those who have 
limited metastatic disease, as opposed to those with extensive disease who 
would be too weak and unwell to withstand systemic therapies. Hence, the 
CTC counts in this patient group will be in the lower range and will require 
amplification of DNA prior to analysis in order to obtain the quantity 
necessary. 
 
Whole genome amplification using the Ampli1™ kit was used to obtain 
sufficient DNA of high quality. Despite the tiny volumes of reagents and the 
intricate steps in the process, the Ampli1™ kit is well designed and worked 
effectively. However, the whole process takes approximately 14 hours and in 
most laboratories would need to be performed over 2 days. 
 
After amplification of DNA from harvested CTCs, it was found that the 
KRBR™ kit was able to detect a mutation when as few as 10 tumour cells had 
been spiked into a 10ml volume of whole blood. This is similar to the detection 
rate found in other studies such as the IsoFlux system (who performed 
amplification of recovered cell DNA using the Repli-G kit) where 9 recovered 
cells from 7ml of whole blood yielded a positive result [138]. Crucially though, 
this was the number of cells shown to have been recovered as opposed to the 
original quantity spiked into whole blood (which was not stated). The assay 
from spiked samples in this study therefore has a lower limit of detection and 
shows promise. 
 
Entrogen’s KRBR™ kit has several practical deficiencies and other groups 
have also found limitations with false negative results amongst patients [135]. 
The kit often needed more than the amount of DNA stated by the 
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manufacturers to perform successful reactions. The ASB-PCR kit by Taqman 
was shown to have a higher sensitivity (0.2%) when tested on spiked samples 
and detected a higher proportion of mutations than Entrogen’s kit and 
therefore may be worth trialling in future experiments [135].  
 
With increasing availability of next generation sequencing (NGS) at cost-
effective pricing [156], the issue of white blood cell contamination can be 
overcome by sequencing all amplified PCR products with almost complete 
inclusion. This means that sensitivity is significantly increased and competing 
gene copies from white blood cells do not interfere with detection of mutations 
within CTCs. NGS also allows simultaneous mutational analysis of multiple 
genes. Another new technology that will negate the effects of background 
signal from contaminating white blood cells is digital droplet PCR, where a 
single suspension containing both tumour and leukocyte cells will be divided 
into ~20,000 droplets and each individual droplet analysed separately [157]. 
 
In this study, when the protocol of whole genome amplification and cast PCR 
was used to detect mutations amongst 5 patients found to have a high 
number of CTCs in peripheral blood, the overall concordance rate for KRAS 
status between primary tumour and current CTC population was 60%, with 
one patient not having sufficient DNA and the other having had a mutation in 
the primary tumour which was not detected in the CTCs. However, these are 
preliminary results only. Further patient sample testing should reveal the true 
sensitivity and concordance rate. It should also be noted that further 
experimentation may require a more effective method of mutation analysis 
than the Entrogen kit used here, in order to avoid possible false-negative 
results. 
 
Increasingly, the analysis of individual CTCs is showing remarkable intra-
patient KRAS mutation heterogeneity [142] and may be the reason underlying 
discordance between tumour and CTC status as found with one of the 
patients in this study. Indeed, the presence of KRAS mutated CTCs in 
patients with KRAS wild-type primary colon carcinomas might be one 
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explanation for failure of drug-mediated EGFR inhibition in these patients [92, 
158].  
 
The analysis of CTCs in the peripheral blood, acting as a ‘liquid biopsy’ has 
tremendous potential to aid our understanding of tumour cell dissemination 
and provide therapies to prevent metastatic disease in the future. However, it 
is a common deficiency of currently available forms of cell capture that its not 
possible to be certain that all the tumour cells present in blood are being 
captured. It is also not possible to be certain that all the cells being captured 
using markers (eg epithelial cell antigens) are actually neoplastic cells and not 
simply benign or normal cells. Unfortunately Parsortix has an additional 
weakness in that its current capture efficiency is less than 50% and therefore 
even if a patient has a high number of CTCs which could be identified using 
the epithelial antibodies being used, a significant number may be lost, 
impeding the opportunity to obtain sufficient quantity to perform mutational 
analysis. This also makes enumeration of CTCs and clinical utility as a 
predictor of prognosis unreliable since false-negative results may be obtained.  
 
Given that the method of cell capture has been modified to process larger 
volumes using Ficoll-density gradient centrifugation the capture efficiency of 
Parsortix should be re-tested. The use of density gradient centrifugation 
means that loss of cells will be inevitable at this early stage as well, since 
maximum recovery rate is reported at around 70% [46]. The spiked 
experiments carried out with the PC3 cells, which are reported to be large 
enough  (~17 µm) to be trapped in the pores of the cassettes being used (8 
µm), suggests there may be other factors causing loss of cells. There may be 
changes in the driving pressure as the filter gradually clogs with trapped cells, 
which could be overcome with the design of a constant pressure system. As 
the design of the machine has undergone modifications after this study was 
undertaken, with the latest prototype utilising a Windows based software to 
monitor pressure changes, this may no longer be a factor.  
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Other reasons for cell lysis may be due to rupture of cells. Experiments have 
shown membrane rupture occurs when the membrane tension exceeds 3% 
[159] of the normal value which may be as little as 3mN/m [160]. Zheng et al. 
felt that in their filtration model, cell damage could be occurring either at the 
initial stages when the cell membrane interacts with the pore edge to when its 
fully trapped, or from the time of full entrapment to the end of the filtration 
process when the cell experiences static pressure. At the constant pressure 
they used, they estimated the cytoplasm membrane tension to be 13.8 mN/m 
which could therefore cause cell damage [46]. Similar studies may be needed 
with Parsortix to calculate the pressures the cells are subjected to and 
examine for evidence of cell rupture. If capture rate is inadequate despite lack 
of evidence for cell rupture, redesign of the filtration membrane may be 
needed. Some groups have reported high capture efficiency in the range of 
90% with the use of dual layer membrane filters [46] and this may be a design 
concept the manufacturers could consider.  
 
Another factor hampering the clinical utility is that with immunohistochemical 
staining of captured cells it takes a trained technician with experience of 
immunohistochemistry (or in the clinical setting a medical pathologist) to 
interpret the results after staining is performed. For each cassette being 
examined, it can take up to an hour or more to accurately enumerate the 
number of CTCs captured, which limits the number of samples that can be 
analysed in the clinical setting and the number of experiments that can be 
performed in a time-limited research study. Furthermore, even with high 
magnification and re-examination of cells by a second investigator, there still 
remains a subjective element when identifying CTCs. Automatic scanning of 
stained cassettes and capturing images of potential CTCs could make this 
step more efficient but will have cost implications with purchase of specialist 
equipment.  
 
If Parsortix is to take a leading role in the mutational analysis field, it must 
continue to develop its technology to improve the capture and harvest 
efficiency, increase processing volume and further eliminate contaminating 
cells within the harvest. If these aspects are developed then it will be a 
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clinically relevant technology for enriching and isolating intact CTCs that could 
be marketed as a low cost, user friendly and effective tool in the fast growing 
field of mutational analysis and personalised cancer care.  
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Appendix 1: 
 
Protocol for capture of CTCs, whole genome 
amplification and KRAS mutational analysis 
 
 
Capture of CTCs from peripheral blood using Parsortix 
 
 
1. Collect 30ml of peripheral whole blood in EDTA (purple) tubes 
2. Ficoll-gradient centrifugation 
a. Place 10ml of Histopaque each into 2 x 50ml universal tubes (A) 
b. In 2 other universal tubes (B) dilute 15ml of whole blood with 15ml 
Hanks solution  
c. Carefully layer the 30ml of diluted blood from each tube B onto the 
Histopaque in each tube A 
d. Centrifuge at 650g for 25 minutes (Programme 2) 
e. Using a 25ml pipette, carefully remove as much of the plasma 
(yellow) layer as possible from each tube and dispose. 
f. Using a 5ml (or 1ml) pipette, carefully collect all of the interphase 
(PBMC) layer from eacg tube (roughly 2-3ml per tube) and place 
into a 10ml EDTA tube 
 
3. Process the 4-6ml of collected solution in a Parsortix machine 
a. Ensure machines are cleaned [PXR_C] and primed [PXR_P] 
b. Separate using PXR_S 
c. On completion of separation, harvest the slide using PXR_H1 
(allows drop by drop collection of captured cells) 
d. Collect drops 9 to 21 only into a PCR (0.2ml) micro centrifuge tube 
4. Centrifuge this at 14,000g for 10 minutes (NB. To secure this in the 
centrifuge, place inside a 0.5ml tube, in turn placed inside a 1.5ml 
Eppindorf tube) 
5. Take off all the excess supernatant, leaving an imaginary micro pellet at 
the base. 
6. Pippette 1µl of (2%) PFA onto the side of the tube and briefly centrifuge 
until at the base.  
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7. Store in -20 0C until use 
8. When 8 patient samples have been collected, continue to WGA 
amplification 
 
 
 
 
Whole Genome Amplification Protocol using Ampli1TM WGA Kit 
 
For more information, refer to the Ampli1™WGA manual.  
 
 
THINGS TO BE DONE PRIOR TO SAMPLE COLLECTION 
DNA to be extracted from A549 cells and diluted to 1ng/µl.  
(A459 cells contain the G12S mutation and therefore can be used as a 
positive control. An alternative would be to use the positive control solution 
from the KRBR™ kit which is positive to ALL 12 mutations..but there is 
only a limited volume of this) 
Pre-prepare Preannealing Reaction Mix (steps 8) 
 
 
1. Prepare “Lysis Reaction Mixture” in a 0.2 mL PCR microtube 
 
 
 
 
 
 
 
 
 
 
 
 
Once the Lysis Reaction Mix is prepared, briefly vortex and spin down 
in order to collect all the mix at the bottom of the tube. 
!"#$%&'()*+,$-).-/,"-)!"#$%0%123%,/)45,1-675-
!"#$%&'()*.!)8%3 )9-5:%,/);& #2<-)=),0)&>
?@ !"#$%&'()*.!)#5,1-675-)2/6)5-213%,/
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Eight samples with a negative control (1uL H2O) and a positive control (1uL of 
DNA 1ng/uL) should be processed in each run. The negative control should 
be processed as the first sample and the positive control should be processed 
as the last sample to avoid contamination. 
 
The negative control is 1uL of Ampli1 Water (provided with kit) 
The positive control is 1ul of DNA extracted from A549 cells 
 
Carry out all steps inside a clean laminar flow hood 
Clean pipettes with 70% EtOH prior to use (or use pipettes dedicated to PCR 
work) 
 
 128 
 
2. Add 2 µl of Lysis Reaction Mix to each of the 10 sample tubes (8 
patient samples, 1 negative control and 1 positive control) by pipetting 
2 µl onto the wall of each tube without touching the sample at the base. 
Briefly spin all the sample tubes prior to placing them in the thermal 
cycler.  
Total volume in each 0.2µl sample tube at this point = 3µl 
 
3. Incubate samples in the thermocycler using programme “WGA_1” 
 
 
Temperature [0C] Hold Volume [µl] 
42 45 minutes  
3 65 30 minutes 
80 15 minutes 
4 ∞ 
 
Once the thermocycler has reached 40C, remove the sample tubes and 
store them at -40C whilst preparing the mix for the next step. 
 
[NB. For convenience the incubation at 420C can be extended 
overnight as long as the enzyme inactivation steps of 30 minutes at 
650C and 15 minutes at 420C is carried out at the end] 
 
 
4. Prepare “Digestion Reaction Mix” in a 0.2mL PCR micro centrifuge 
tube 
 
 
 
 
 
 
 
 
 
Once the Digestion Reaction Mix is prepared, briefly vortex and spin 
down in order to collect all the mix at the bottom of the tube. 
 
5. Add 2µl of the Digestion Reaction Mix onto the wall of each sample 
tube above the liquid already present, without touching it. Briefly spin 
all the sample tubes prior to placing them in the thermal cycler.  
Total volume in each 0.2µl sample tube at this point = 5µl 
 
 
6. Incubate using programme “WGA_2” 
 
Temperature [0C] Hold Volume [µl] 
37 5 minutes  
5 65 5 minutes 
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4 ∞ 
 
 
7. Either store at 40C whilst preparing annealing reaction mix or use the 
pre-prepared stock.  
 
[The Preannealing Reaction Mix can be pre-made and stored at -200C, 
which saves time once the samples have been collected and are being 
processed. Otherwise samples can be stored at 40C whilst this mix is 
being made.] 
 
8. Prepare the Preanneaing Reaction Mix in 0.2ml PCR micro centrifuge 
tube 
 
Vial Label Cap color Volume per 1 
reaction [µl] 
Volume per 
10 reactions 
[µl] 
R1 Ampli1TM 
Reaction Buffer 1 
White 0.5 5.0 
R4 Ampli1TM 
Reagent 4 
Yellow 0.5 5.0 
R5 Ampli1TM 
Reagent 5 
Yellow 0.5 5.0 
H2O Ampli1TM Water Colorless 1.5 15.0 
  Per 
reaction 
3.0 30.0 
 
Once the mix is prepared briefly vortex and spin down in order to 
collect all the reaction mix.  
 
 Do not add Preannealing Reaction Mix to the samples! 
 
Incubate the Preannealing Reaction mix in the thermal cycler using 
programme “WGA_3” 
 
Cycle 
Numbers 
Temperature [0C] Hold Volume [µl] 
1 65* 1 minute  
30µl  ↓ 1 minute 
 15 1 minute 
1 4 ∞ 
 
* start at 650C for 1 min incubation and then reduce for 10C per cycle 
incubating for 1 minute at each temperature until +150C 
 
(This Mix can either be stored at -200C or be used immediately in the 
ligation reaction) 
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9. Prepare the Ligation reaction mix in 0.2mL PCR micro centrifuge tube 
 
Vial Label Cap color Volume per 1 
reaction [µl] 
Volume per 
10 reactions 
[µl] 
 Preannealing 
reaction mix 
 3.0 30.0 
R6 Ampli1TM 
Reagent 6 
Green 1.0 10.0 
E3 Ampli1TM 
Enzyme 3 
Green 1.0 10.0 
  Per 
reaction 
5.0 50.0 
 
 
Once the mix is prepared briefly vortex and spin down in order to 
collect all the reaction mix.  
 
10. Add 5µl of the Ligation Reaction Mix onto the wall of each sample tube 
above the liquid already present, without touching it. Briefly spin all the 
sample tubes prior to placing them in the thermal cycler.  
Total volume in each 0.2mL sample tube at this point = 10µl 
 
11. Incubate using Programme “WGA_4” (NB. This can be extended to an 
overnight incubation) 
 
Temperature [0C] Hold Volume [µl] 
15 1 hour 10 
15 ∞ 
 
 
12.  Store samples at 4 C whilst preparing next step 
 
13. Prepare the primary PCR reaction mix in a 1.5ml Eppindorf tube 
 
Vial Label Cap color Volume per 1 
reaction [µl] 
Volume per 
10 reactions 
[µl] 
R7 Ampli1TM 
Reaction Buffer 7 
Purple 3.0 30.0 
R8 Ampli1TM 
Reagent 8 
Purple 2.0 20.0 
E4 Ampli1TM 
Enzyme 5 
Purple 1.0 10.0 
H2O Ampli1TM Water Colorless 34.0 340.0 
  Per 
reaction 
40.0 400.0 
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Once the mix is prepared briefly vortex and spin down in order to 
collect all the reaction mix.  
 
 
14. Add 40µl of the Primary PCR Reaction Mix onto the wall of each 
sample tube above the liquid already present, without touching it. 
Briefly spin all the sample tubes prior to placing them in the thermal 
cycler.  
Final volume in each sample tube = 50µl 
 
15. Incubate using programme “WGA_5” 
 
Cycle 
Numbers 
Temperature 
[0C] 
Hold Additional time 
and 
temperature 
Volume 
[µl] 
 68 3 minutes   
14 94 
57 
68 
40 sec 
30 sec 
1:30* min:sec 
*= +1 sec/cycle  
50µl 
8 94 
57** 
68 
40 sec 
30 sec 
1:45* min:sec 
**= +10C/cycle 
*= +1 sec/cycle 
22 94 
65 
68 
40 sec 
30 sec 
1:53* min:se 
*= +1 sec/cycle 
1 68 
4 
3:40 min:sec 
∞ 
 
 
 
 
16. Store samples at -20°C 
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Testing for KRAS mutation using the KRBR™-Kit by Entrogen 
 
For more information or more detailed protocol, refer to the KRBR™ kit 
handbook. 
 
 
 
1. Dilute extracted DNA to 30ng/µl.  
 
2. Thaw all primer/probe mixes, positive control mix and 2x reaction 
master mix 
 
3. Each reaction will be 30µl in total and consist of the following: 
  
 2 x PCR reaction mix  15µl 
 Primer mix    6µl 
 DNA sample    10-30ng (up to 9µl) 
 Molecular grade water   adjust to total 30µl 
 
Therefore, to carry out twelve reactions, checking for all KRAS mutations,   
make up the following “Sample master mix” for each patient (with 5% 
overage),  
 
 
 
 
 
Reagents Volume per Volume for 12 
Thaw one vial of Reaction Mix at a time, which can be stored at 4-80C 
(max 3 weeks) 
Protect primer/probe mix from light 
Centrifuge primer/probe mix tubes before opening 
Carry out DNA isolation and PCR steps in separate areas to avoid 
cross-contamination 
Wipe down work area with 70% ethanol and spray clean the pipettes 
Always wear gloves 
 
Probes complementing KRAS mutant genes are tagged with FAM, the 
probe complementary to the endogenous gene is tagged with VIC (to 
indicate that there is sufficient amplifiable DNA template in the reaction, 
therefore a VIC signal should be detected in all samples, whilst FAM is 
only seen in samples with mutations).  
 
As our PCR machine does not have the VIC filter, we have to use 
HEX (which has similar absorption/emission wavelengths) 
 
To test for all 12 KRAS mutations, a total of 120-360ng of DNA is 
needed  
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reaction reactions (+5% 
overage) 
2x Reaction master mix 15µl 189µl 
DNA (assuming 20ng in 1µl*)/ 
Positive Control/  
Negative Control (Nuclease 
free water)  
1µl 12.6µl 
Nuclease water 8µl 100.8µl 
* If higher volumes of DNA are needed to obtain 30ng in total, reduce 
nuclease free water volume accordingly, to total 30µl per reaction  
 
4. Mix by vortexing for 10 seconds 
 
5. Centrifuge at 10,000 rpm at room temperature for 5 seconds 
 
6. Dispense 24µl of this sample master mix into each well of a single row 
as shown below 
 
7. Add 6µl of each primer/probe mix to its corresponding well and mix well 
by pipetting up and down several times 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8. Seal the plate with optical sealing film 
 
9. Briefly centrifuge and check all wells are of equal volume and there are no 
air bubbles in the solution 
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10. Place 96-well plate in PCR machine 
 
11. Turn on PCR machine and laptop; open PCR programme (“MxPro”) and 
select “Comparative Quantitation” for type of experiment. 
 
12. Select all wells as “Unknown” and choose to measure HEX and FAM 
fluorescence 
 
 
13. Set up the thermo-profile:  
 
 
 
14. Run the PCR 
 
15. In Analysis, select “text report” and obtain the well Ct value for HEX and 
FAM. (The Ct value should be automatically set to determine the 
exponential growth phase of the fluorescence) 
 
16. In analyzing the results, look at each reaction’s HEX (VIC) Ct value first to 
determine if sufficient DNA was put in each reaction: 
 
17. If the reaction’s HEX Ct is between 25 and 30, then look at the FAM Ct to 
determine if the specific mutation was present in the DNA sample: 
 
If FAM/green Ct is: Mutation Status 
38.5 or lower Positive 
Above 38.5 or no signal Negative 
 
 
Note: Due to cross-reactivity, some samples may have positive signals for 
multiple mutations. In such cases, the sample is positive only for the mutation 
that corresponds to the reaction with the most prominent signal (lowest Ct 
value). 
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Z> O0-5H(K!>((b.*(T,1(,02.(2,W7(+B-2(D4.6-07(6.4(6*+*47(*27(*2-/:(+B7($,W7(#2(F*++./(,+(+B7(+.D(.6(+B7(
E-,0.:(F.G>(
c> <.(+.(8-7C[<,-/(KD+-T-_,+-./=(27075+(#00(OB,//702(64.T(+B7(OB,//70($7++-/:2(E4.D(E.C/=(,/E(5B75H(
+B7(F.G(/7G+(+ (N746.4T(KD+-T-_,+-./(&76.47(?2+(#5a*-2-+-./>((R.+7P(SB-2(2+7D(-2(./01(/75722,41(+.(
D746.4T(./57(6.4(7,5B(/7C(F,+5B(.6(47,:7/+2>((K/57(+B7(<,-/(27++-/:2(,47(E7+74T-/7E=(*27(+B7(2,T7(
27++-/:2(6.4(6*+*47(4*/2(C-+B(47,:7/+2(C-+B(+B7(2,T7(F,+5B(/*TF74>(
A> ^.,E(+B7(2+4-D(+*F72(-/+.(+B7(4.+.4>(
?I> <.(+.("*/[$+,4+("*/=(+B7/(50-5H(./(+B7($+,4+(F*++./(+.(F7:-/(+B7(4*/>(
(
If HEX/yellow Ct is: Analysis Description Action 
Between 25 and 30 Ideal Ct range Continue with step 17 
Below 25 Overloaded reaction Dilute DNA and re-test 
Above 30 Insufficient DNA Increase the DNA input 
per reaction and re-test 
Not present One of the reaction 
components or DNA 
was not added correctly 
The test for that 
particular sample has 
failed, don’t continue 
with analysis. 
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